

# Alberto Ortiz

## List of Publications by Year in descending order

Source: [//exaly.com/author-pdf/7087973/publications.pdf](https://exaly.com/author-pdf/7087973/publications.pdf)

Version: 2024-02-01

778  
papers

103,911  
citations

2173

96  
h-index

229

297  
g-index

867  
all docs

867  
docs citations

867  
times ranked

121230  
citing authors

#	ARTICLE	IF	CITATIONS
1	International comparison and time trends of first kidney transplant recipient characteristics across Europe: an ERA Registry study. <i>Nephrology Dialysis Transplantation</i> , 2024, 39, 648-658.	0.7	2
2	Serum phosphate is associated with increased risk of bone fragility fractures in haemodialysis patients. <i>Nephrology Dialysis Transplantation</i> , 2024, 39, 618-626.	0.7	2
3	Should we enlarge the indication for kidney biopsy in diabetics? The con part. <i>CKJ: Clinical Kidney Journal</i> , 2024, 17, .	2.7	1
4	The ERA Registry Annual Report 2021: a summary. <i>CKJ: Clinical Kidney Journal</i> , 2024, 17, .	2.7	10
5	Uromodulin biology. <i>Nephrology Dialysis Transplantation</i> , 2024, 39, 1073-1087.	0.7	2
6	A European Renal Association (ERA) synopsis for nephrology practice of the 2023 European Society of Hypertension (ESH) Guidelines for the Management of Arterial Hypertension. <i>Nephrology Dialysis Transplantation</i> , 2024, 39, 929-943.	0.7	3
7	Sex disparities in mortality and cardiovascular outcomes in chronic kidney disease. <i>CKJ: Clinical Kidney Journal</i> , 2024, 17, .	2.7	1
8	Decreased life expectancy: a health outcome not corrected by kidney replacement therapy that emphasizes the need for primary prevention of CKD. <i>CKJ: Clinical Kidney Journal</i> , 2024, 17, .	2.7	2
9	Performances of acute kidney injury biomarkers vary according to sex. <i>CKJ: Clinical Kidney Journal</i> , 2024, 17, .	2.7	0
10	Chronic kidney disease and the global public health agenda: an international consensus. <i>Nature Reviews Nephrology</i> , 2024, 20, 473-485.	9.3	23
11	Sixty years of European Renal Association (ERA) Registry data on kidney disease: visualizing differences in clinical practice. <i>Nephrology Dialysis Transplantation</i> , 2024, 39, 897-900.	0.7	0
12	Heterogeneity in the incidence of kidney replacement therapy across Europe: a benchmarking tool to improve clinical practice. <i>CKJ: Clinical Kidney Journal</i> , 2024, 17, .	2.7	0
13	Genetic Characterization of Kidney Failure of Unknown Etiology in Spain: Findings From the GENSEN Study. <i>American Journal of Kidney Diseases</i> , 2024, , .	1.9	0
14	Prognostic and therapeutic monitoring value of plasma and urinary cytokine profile in primary membranous nephropathy: the STARMEN trial cohort. <i>CKJ: Clinical Kidney Journal</i> , 2024, 17, .	2.7	0
15	Mineralocorticoid receptor antagonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2023, 38, 10-25.	0.7	36
16	Obesity, chronic kidney disease progression and the role of the adipokine C1q/TNF related protein-3. <i>Nefrología</i> , 2023, 43, 328-334.	0.6	3
17	From cardiorenal syndromes to cardioneurology: a reflection by nephrologists on renocardiac syndromes. <i>CKJ: Clinical Kidney Journal</i> , 2023, 16, 19-29.	2.7	3
18	Renal artery stenting in the correct patients with atherosclerotic renovascular disease: time for a proper renal and cardiovascular outcome study?. <i>CKJ: Clinical Kidney Journal</i> , 2023, 16, 201-204.	2.7	2

#	ARTICLE	IF	CITATIONS
19	Ageing meets kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2023, 38, 523-526.	0.7	8
20	SGLT-2 inhibitors in nephrotic-range proteinuria: emerging clinical evidence. <i>CKJ: Clinical Kidney Journal</i> , 2023, 16, 52-60.	2.7	16
21	Increasing numbers and improved overall survival of patients on kidney replacement therapy over the last decade in Europe: an ERA Registry study. <i>Nephrology Dialysis Transplantation</i> , 2023, 38, 1027-1040.	0.7	17
22	The association between acute kidney injury and outcomes in cancer patients receiving immune checkpoint inhibitor therapy: a systematic review and meta-analysis. <i>CKJ: Clinical Kidney Journal</i> , 2023, 16, 817-826.	2.7	10
23	PoCUS in nephrology: a new tool to improve our diagnostic skills. <i>CKJ: Clinical Kidney Journal</i> , 2023, 16, 218-229.	2.7	15
24	Novel strategies in nephrology: what to expect from the future?. <i>CKJ: Clinical Kidney Journal</i> , 2023, 16, 230-244.	2.7	7
25	Donor liquid biopsy and outcomes in kidney transplantation. <i>CKJ: Clinical Kidney Journal</i> , 2023, 16, 447-455.	2.7	1
26	Chronic kidney disease as cardiovascular risk factor in routine clinical practice: a position statement by the Council of the European Renal Association. <i>CKJ: Clinical Kidney Journal</i> , 2023, 16, 403-407.	2.7	6
27	Chronic kidney disease as cardiovascular risk factor in routine clinical practice: a position statement by the Council of the European Renal Association. <i>Nephrology Dialysis Transplantation</i> , 2023, 38, 527-531.	0.7	12
28	Acute and chronic kidney disease and risk of hospital mortality during COVID-19 pandemic waves in the pre-vaccination era. <i>CKJ: Clinical Kidney Journal</i> , 2023, 16, 374-383.	2.7	1
29	Impact of public restrictive measures on hypertension during the COVID-19 pandemic: existing evidence and long-term implications. <i>CKJ: Clinical Kidney Journal</i> , 2023, 16, 619-634.	2.7	6
30	Preparing European Nephrology for the next pandemic: lessons from the ERACODA collaboration. <i>Nephrology Dialysis Transplantation</i> , 2023, 38, 575-582.	0.7	2
31	Autosomal dominant polycystic kidney disease in young adults. <i>CKJ: Clinical Kidney Journal</i> , 2023, 16, 985-995.	2.7	3
32	Humoral response after the fourth dose of the SARS-CoV-2 vaccine in the CKD spectrum: a prespecified analysis of the SENCOVAC study. <i>Nephrology Dialysis Transplantation</i> , 2023, 38, 969-981.	0.7	20
33	Tirzepatide and prevention of chronic kidney disease. <i>CKJ: Clinical Kidney Journal</i> , 2023, 16, 797-808.	2.7	18
34	Prevention of cardiorenal damage: importance of albuminuria. <i>European Heart Journal</i> , 2023, 44, 1112-1123.	2.2	21
35	Intravenous fluid therapy in accordance with kidney injury risk: when to prescribe what volume of which solution. <i>CKJ: Clinical Kidney Journal</i> , 2023, 16, 684-692.	2.7	3
36	The transcription factor Fosl1 preserves Klotho expression and protects from acute kidney injury. <i>Kidney International</i> , 2023, 103, 686-701.	5.3	12

#	ARTICLE	IF	CITATIONS
37	Type IV Collagen and SOX9 Are Molecular Targets of BET Inhibition in Experimental Glomerulosclerosis. <i>International Journal of Molecular Sciences</i> , 2023, 24, 486.	4.1	6
38	Vitamin D, Cellular Senescence and Chronic Kidney Diseases: What Is Missing in the Equation?. <i>Nutrients</i> , 2023, 15, 1349.	4.1	5
39	Novel Aspects of the Immune Response Involved in the Peritoneal Damage in Chronic Kidney Disease Patients under Dialysis. <i>International Journal of Molecular Sciences</i> , 2023, 24, 5763.	4.1	12
40	Regulated cell death pathways in kidney disease. <i>Nature Reviews Nephrology</i> , 2023, 19, 281-299.	9.3	78
41	Maintenance of Potent Cellular and Humoral Immune Responses in Long-Term Hemodialysis Patients after 1273-mRNA SARS-CoV-2 Vaccination. <i>Pharmaceuticals</i> , 2023, 16, 574.	3.8	3
42	Atherosclerotic renovascular disease: a clinical practice document by the European Renal Best Practice (ERBP) board of the European Renal Association (ERA) and the Working Group Hypertension and the Kidney of the European Society of Hypertension (ESH). <i>Nephrology Dialysis Transplantation</i> , 2023, 38, 2835-2850.	0.7	4
43	Mitochondrial Dysfunction in the Cardio-Renal Axis. <i>International Journal of Molecular Sciences</i> , 2023, 24, 8209.	4.1	4
44	Natremia after fasting 12h, kidney disease and aging. <i>EBioMedicine</i> , 2023, 92, 104637.	5.9	0
45	A Policy Call to Address Rare Kidney Disease in Health Care Plans. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2023, 18, 1510-1518.	4.3	3
46	Dynamics of urine proteomics biomarker and disease progression in patients with IgA nephropathy. <i>Nephrology Dialysis Transplantation</i> , 2023, 38, 2826-2834.	0.7	3
47	Mineral and bone metabolism markers and mortality in diabetic patients on haemodialysis. <i>Nephrology Dialysis Transplantation</i> , 2023, 38, 2589-2597.	0.7	3
48	Mineralocorticoid receptor antagonist use in chronic kidney disease with type 2 diabetes: a clinical practice document by the European Renal Best Practice (ERBP) board of the European Renal Association (ERA). <i>CKJ: Clinical Kidney Journal</i> , 2023, 16, 1885-1907.	2.7	9
49	Optimization of potassium management in patients with chronic kidney disease and type 2 diabetes on finerenone. <i>Expert Review of Clinical Pharmacology</i> , 2023, 16, 519-531.	3.1	1
50	BET Protein Inhibitor JQ1 Modulates Mitochondrial Dysfunction and Oxidative Stress Induced by Chronic Kidney Disease. <i>Antioxidants</i> , 2023, 12, 1130.	5.1	1
51	Time-Dependent Changes of Klotho and FGF-23 Levels after Kidney Transplantation: Role of Cold Ischemia Time, Renal Function and Graft Inflammation. <i>Journal of Clinical Medicine</i> , 2023, 12, 4486.	2.5	0
52	Selective glomerular hypofiltration syndrome. <i>Nephrology Dialysis Transplantation</i> , 2023, 39, 10-17.	0.7	6
53	Chronic kidney disease: the missing concept in the 2019 EULAR/ERA-EDTA recommendations for lupus nephritis. <i>Nephrology Dialysis Transplantation</i> , 2023, 39, 151-158.	0.7	2
54	CCN2 Activates RIPK3, NLRP3 Inflammasome, and NRF2/Oxidative Pathways Linked to Kidney Inflammation. <i>Antioxidants</i> , 2023, 12, 1541.	5.1	2

#	ARTICLE	IF	CITATIONS
55	Prognosis and Personalized In Silico Prediction of Treatment Efficacy in Cardiovascular and Chronic Kidney Disease: A Proof-of-Concept Study. <i>Pharmaceuticals</i> , 2023, 16, 1298.	3.8	5
56	Increased expression of SCARF genes favoring SARS-CoV-2 infection in key target organs in CKD. <i>CKJ: Clinical Kidney Journal</i> , 2023, 16, 2672-2682.	2.7	2
57	SCARF Genes in COVID-19 and Kidney Disease: A Path to Comorbidity-Specific Therapies. <i>International Journal of Molecular Sciences</i> , 2023, 24, 16078.	4.1	0
58	Interaction of Fabry Disease and Diabetes Mellitus: Suboptimal Recruitment of Kidney Protective Factors. <i>International Journal of Molecular Sciences</i> , 2023, 24, 15853.	4.1	0
59	BET Protein Inhibitor JQ1 Ameliorates Experimental Peritoneal Damage by Inhibition of Inflammation and Oxidative Stress. <i>Antioxidants</i> , 2023, 12, 2055.	5.1	0
60	EDTAKI: a Nephrology and Public Policy Committee platform call for more European involvement in acute kidney injury. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 740-748.	0.7	5
61	Use of chronic kidney disease blind spot to prevent cardiorenal outcomes. <i>European Heart Journal</i> , 2022, 43, 257-260.	2.2	5
62	RICORS2040: the need for collaborative research in chronic kidney disease. <i>CKJ: Clinical Kidney Journal</i> , 2022, 15, 372-387.	2.7	58
63	Assessment of hypertension in kidney transplantation by ambulatory blood pressure monitoring: a systematic review and meta-analysis. <i>CKJ: Clinical Kidney Journal</i> , 2022, 15, 31-42.	2.7	16
64	Documento de consenso de poliquistosis renal autosómica dominante del grupo de trabajo de enfermedades hereditarias de la Sociedad Española de Nefrología. Revisión 2020. <i>Nefrología</i> , 2022, 42, 367-389.	0.6	10
65	More on the invisibility of chronic kidney disease and counting. <i>CKJ: Clinical Kidney Journal</i> , 2022, 15, 388-392.	2.7	18
66	Decade-long disease, secondary malignancy, and brainstem injury outcomes in pediatric and young adult medulloblastoma patients treated with proton radiotherapy. <i>Neuro-Oncology</i> , 2022, 24, 1010-1019.	1.2	9
67	Antifibrotic Agents for the Management of CKD: A Review. <i>American Journal of Kidney Diseases</i> , 2022, 80, 251-263.	1.9	38
68	Sarcopenia assessed by 4-step EWGSOP2 in elderly hemodialysis patients: Feasibility and limitations. <i>PLoS ONE</i> , 2022, 17, e0261459.	2.5	12
69	Estimated glomerular filtration rate by formulas in patients with cirrhosis: An unreliable procedure. <i>Liver International</i> , 2022, 42, 884-895.	3.9	3
70	Bone Marrow-Derived RIPK3 Mediates Kidney Inflammation in Acute Kidney Injury. <i>Journal of the American Society of Nephrology: JASN</i> , 2022, 33, 357-373.	0.5	22
71	Molecular Mechanisms of Kidney Injury and Repair. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1542.	4.1	35
72	Fatty kidney: A possible future for chronic kidney disease research. <i>European Journal of Clinical Investigation</i> , 2022, 52, e13748.	3.4	7

#	ARTICLE	IF	CITATIONS
73	Oxidative Stress and Cellular Senescence Are Involved in the Aging Kidney. <i>Antioxidants</i> , 2022, 11, 301.	5.1	29
74	Sodium-glucose cotransporter inhibition in polycystic kidney disease: fact or fiction. <i>CKJ: Clinical Kidney Journal</i> , 2022, 15, 1275-1283.	2.7	12
75	Impact of TiO <sub>2</sub> on structural and spectral properties of ZnS-MoS <sub>2</sub> nanocomposites. <i>Materials Today: Proceedings</i> , 2022, 49, A12-A18.	1.9	2
76	Multiparametric Flow Cytometry versus Conventional Cytology in the Study of Leptomeningeal Involvement in Malignant Hematological Diseases. <i>Laboratory Medicine</i> , 2022, 53, 399-404.	1.0	2
77	Loss of humoral response 3 months after SARS-CoV-2 vaccination in the CKD spectrum: the multicentric SENCOVAC study. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 994-999.	0.7	15
78	Epigenetic Modulation of Gremlin-1/NOTCH Pathway in Experimental Crescentic Immune-Mediated Glomerulonephritis. <i>Pharmaceuticals</i> , 2022, 15, 121.	3.8	8
79	Early glomerular filtration rate changes in living kidney donors and recipients: an example of renal plasticity. <i>CKJ: Clinical Kidney Journal</i> , 2022, 15, 885-894.	2.7	1
80	Stopping kidney protection in the elderly following acute kidney injury: think mortality. <i>CKJ: Clinical Kidney Journal</i> , 2022, 15, 1037-1040.	2.7	1
81	Solving the riddle of Aguascalientes nephropathy: nephron number, environmental toxins and family clustering. <i>CKJ: Clinical Kidney Journal</i> , 2022, 15, 1226-1230.	2.7	3
82	Ferrostatin-1 modulates dysregulated kidney lipids in acute kidney injury. <i>Journal of Pathology</i> , 2022, 257, 285-299.	4.4	16
83	Blood pressure targets in CKD 2021: the never-ending guidelines debacle. <i>CKJ: Clinical Kidney Journal</i> , 2022, 15, 845-851.	2.7	16
84	CCN2 (Cellular Communication Network Factor 2) Deletion Alters Vascular Integrity and Function Predisposing to Aneurysm Formation. <i>Hypertension</i> , 2022, 79, e42-e55.	4.9	12
85	Wasp stings and plasma exchange. <i>CKJ: Clinical Kidney Journal</i> , 2022, 15, 1455-1458.	2.7	2
86	Probiotics for kidney disease. <i>CKJ: Clinical Kidney Journal</i> , 2022, 15, 1981-1986.	2.7	5
87	Evaluation of the impact of an intradialytic exercise programme on sarcopaenia in very elderly haemodialysis patients. <i>CKJ: Clinical Kidney Journal</i> , 2022, 15, 1514-1523.	2.7	11
88	Estimated GFR in autosomal dominant polycystic kidney disease: errors of an unpredictable method. <i>Journal of Nephrology</i> , 2022, 35, 2109-2118.	2.1	7
89	Who killed Bruce Lee? The hyponatraemia hypothesis. <i>CKJ: Clinical Kidney Journal</i> , 2022, 15, 2169-2176.	2.7	1
90	Extracellular Vesicles and Acute Kidney Injury: Potential Therapeutic Avenue for Renal Repair and Regeneration. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3792.	4.1	10

#	ARTICLE	IF	CITATIONS
91	The role of body mass index on IgA nephropathy prognosis: a systematic review and meta-analysis. <i>International Urology and Nephrology</i> , 2022, 54, 2567-2579.	1.4	2
92	Growth differentiation factor-15 preserves Klotho expression in acute kidney injury and kidney fibrosis. <i>Kidney International</i> , 2022, 101, 1200-1215.	5.3	35
93	Benchmarking CKD: incidence of CKD in a European country with low prevalence of CKD and kidney replacement therapy. <i>CKJ: Clinical Kidney Journal</i> , 2022, 15, 1221-1225.	2.7	2
94	Triglycerides and glucose index and the risk of cardiovascular events in persons with non-diabetic chronic kidney disease. <i>CKJ: Clinical Kidney Journal</i> , 2022, 15, 1705-1712.	2.7	8
95	Increased 1-year mortality in haemodialysis patients with COVID-19: a prospective, observational study. <i>CKJ: Clinical Kidney Journal</i> , 2022, 15, 432-441.	2.7	27
96	The last pre-pandemic European Renal Association Registry report: age at start of kidney replacement therapy in Europe. <i>CKJ: Clinical Kidney Journal</i> , 2022, 15, 393-396.	2.7	5
97	Renin-angiotensin system blockers during the COVID-19 pandemic: an update for patients with hypertension and chronic kidney disease. <i>CKJ: Clinical Kidney Journal</i> , 2022, 15, 397-406.	2.7	10
98	Recent Clinical Trials Insights into the Treatment of Primary Membranous Nephropathy. <i>Drugs</i> , 2022, 82, 109-132.	10.8	16
99	The unmet need of evidence-based therapy for patients with advanced chronic kidney disease and heart failure. <i>CKJ: Clinical Kidney Journal</i> , 2022, 15, 865-872.	2.7	19
100	The ERA Registry Annual Report 2019: summary and age comparisons. <i>CKJ: Clinical Kidney Journal</i> , 2022, 15, 452-472.	2.7	63
101	The hidden diabetic kidney disease in a university hospital-based population: a real-world data analysis. <i>CKJ: Clinical Kidney Journal</i> , 2022, 15, 1865-1871.	2.7	6
102	The Use of Healthy Eating Index 2015 and Healthy Beverage Index for Predicting and Modifying Cardiovascular and Renal Outcomes. <i>Current Nutrition Reports</i> , 2022, 11, 526-535.	4.4	4
103	SARS-CoV-2 Infection Evolution Among Nephrologists During the Pandemic: Clinical Features and Impact of Vaccination. <i>Kidney International Reports</i> , 2022, 7, 1686-1689.	0.8	2
104	Humoral Response to Third Dose of SARS-CoV-2 Vaccines in the CKD Spectrum. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2022, 17, 872-876.	4.3	27
105	Repurposing drugs for highly prevalent diseases: pentoxifylline, an old drug and a new opportunity for diabetic kidney disease. <i>CKJ: Clinical Kidney Journal</i> , 2022, 15, 2200-2213.	2.7	4
106	Sarcopenia and Mortality in Older Hemodialysis Patients. <i>Nutrients</i> , 2022, 14, 2354.	4.1	19
107	Gain-of-function <i>TLR7</i> and loss-of-function <i>A20</i> gene variants identify a novel pathway for Mendelian lupus and lupus nephritis. <i>CKJ: Clinical Kidney Journal</i> , 2022, 15, 1973-1980.	2.7	6
108	Rapid, scalable assessment of SARS-CoV-2 cellular immunity by whole-blood PCR. <i>Nature Biotechnology</i> , 2022, 40, 1680-1689.	20.4	31

#	ARTICLE	IF	CITATIONS
109	Ageing meets kidney disease. CKJ: Clinical Kidney Journal, 2022, 15, 1793-1796.	2.7	12
110	Ageing meets kidney disease. Age and Ageing, 2022, 51, .	1.6	7
111	Is Our Increasing Understanding of PCSK9 and Lp(a) Metabolism the Key to Unlocking the Paradox of Statins Ineffectiveness in Reducing Cardiovascular Events in Advanced CKD?. SN Comprehensive Clinical Medicine, 2022, 4, .	0.6	1
112	Tubular Mitochondrial Dysfunction, Oxidative Stress, and Progression of Chronic Kidney Disease. Antioxidants, 2022, 11, 1356.	5.1	38
113	Infectious consequences of the AKI-to-CKD transition. CKJ: Clinical Kidney Journal, 2022, 15, 2237-2244.	2.7	5
114	Anti-Spike antibodies 3 months after SARS-CoV-2 mRNA vaccine booster dose in patients on hemodialysis: the prospective SENCOVAC study. CKJ: Clinical Kidney Journal, 2022, 15, 1856-1864.	2.7	12
115	A pathway of osmotic stress-induced necroptosis. Nature Reviews Nephrology, 2022, 18, 609-610.	9.3	6
116	Impact of different COVID-19 waves on kidney replacement therapy epidemiology and mortality: REMER 2020. Nephrology Dialysis Transplantation, 2022, 37, 2253-2263.	0.7	11
117	Chronic kidney disease as cardiovascular risk factor in routine clinical practice: a position statement by the Council of the European Renal Association. European Journal of Preventive Cardiology, 2022, 29, 2211-2215.	1.8	17
118	Postbiotics and Kidney Disease. Toxins, 2022, 14, 623.	3.4	8
119	Urinary Protein Profiling for Potential Biomarkers of Chronic Kidney Disease: A Pilot Study. Diagnostics, 2022, 12, 2583.	2.7	4
120	Enhanced Cardiorenal Protective Effects of Combining SGLT2 Inhibition, Endothelin Receptor Antagonism and RAS Blockade in Type 2 Diabetic Mice. International Journal of Molecular Sciences, 2022, 23, 12823.	4.1	13
121	Long-Term Dynamic Humoral Response to SARS-CoV-2 mRNA Vaccines in Patients on Peritoneal Dialysis. Vaccines, 2022, 10, 1738.	4.4	6
122	Major dietary patterns in relation to preeclampsia among Iranian pregnant women: a caseâ€“control study. Journal of Maternal-Fetal and Neonatal Medicine, 2021, 34, 3529-3536.	1.7	11
123	Incidence for volar locking plate removal following distal radius fracture surgery. Archives of Orthopaedic and Trauma Surgery, 2021, 141, 1297-1302.	2.5	10
124	Coronary artery disease in dialysis patients: evidence synthesis, controversies and proposed management strategies. Journal of Nephrology, 2021, 34, 39-51.	2.1	4
125	Bisphenol S is a haemodialysis-associated xenobiotic that is less toxic than bisphenol A. CKJ: Clinical Kidney Journal, 2021, 14, 1147-1155.	2.7	14
126	The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy. Kidney International, 2021, 99, 986-998.	5.3	126



#	ARTICLE	IF	CITATIONS
127	Agalsidase beta treatment slows estimated glomerular filtration rate loss in classic Fabry disease patients: results from an individual patient data meta-analysis. CKJ: Clinical Kidney Journal, 2021, 14, 1136-1146.	2.7	12
128	A primer on metabolic memory: why existing diabetes treatments fail. CKJ: Clinical Kidney Journal, 2021, 14, 756-767.	2.7	5
129	Reverse pseudohyperkalemia is more than leukocytosis: a retrospective study. CKJ: Clinical Kidney Journal, 2021, 14, 1443-1449.	2.7	5
130	Slo-Mo anti-neutrophil cytoplasmic antibody-associated renal vasculitis. CKJ: Clinical Kidney Journal, 2021, 14, 18-22.	2.7	0
131	Intravenous iron therapy and the cardiovascular system: risks and benefits. CKJ: Clinical Kidney Journal, 2021, 14, 1067-1076.	2.7	15
132	Chronic kidney disease is a key risk factor for severe COVID-19: a call to action by the ERA-EDTA. Nephrology Dialysis Transplantation, 2021, 36, 87-94.	0.7	284
133	Optimizing the timing of nephrology referral for patients with diabetic kidney disease. CKJ: Clinical Kidney Journal, 2021, 14, 5-8.	2.7	9
134	The effect of energy restriction on development and progression of chronic kidney disease: review of the current evidence. British Journal of Nutrition, 2021, 125, 1201-1214.	2.6	3
135	Dissimilar regulation of glucose and lipid metabolism by leptin in two strains of gibel carp ( <i>Carassius gibelio</i> ). British Journal of Nutrition, 2021, 125, 1215-1229.	2.6	5
136	Associations between different types and sources of dietary fibre intake and depressive symptoms in a general population of adults: a cross-sectional study. British Journal of Nutrition, 2021, 125, 1281-1290.	2.6	8
137	Serum glycated albumin predicts all-cause mortality in dialysis patients with diabetes mellitus: meta-analysis and systematic review of a predictive biomarker. Acta Diabetologica, 2021, 58, 81-91.	2.5	26
138	Insulin resistance may be misdiagnosed by HOMA-IR in adults with greater fat-free mass: the ELSA-Brasil Study. Acta Diabetologica, 2021, 58, 73-80.	2.5	3
139	Podocyte and tubular involvement in AngioJet-induced kidney injury. CKJ: Clinical Kidney Journal, 2021, 14, 424-428.	2.7	7
140	Development and internal validation of a prediction model for hospital-acquired acute kidney injury. CKJ: Clinical Kidney Journal, 2021, 14, 309-316.	2.7	27
141	Acidosis, cognitive dysfunction and motor impairments in patients with kidney disease. Nephrology Dialysis Transplantation, 2021, 37, ii4-ii12.	0.7	19
142	Suboptimal personal protective equipment and SARS-CoV-2 infection in Nephrologists: a Spanish national survey. CKJ: Clinical Kidney Journal, 2021, 14, 1216-1221.	2.7	6
143	Chronic kidney disease and neurological disorders: are uraemic toxins the missing piece of the puzzle?. Nephrology Dialysis Transplantation, 2021, 37, ii33-ii44.	0.7	35
144	Sodium-glucose co-transporter-2 inhibitors for patients with diabetic and nondiabetic chronic kidney disease: a new era has already begun. Journal of Hypertension, 2021, 39, 1090-1097.	0.5	26

#	ARTICLE	IF	CITATIONS
145	Effect of Coffee Consumption on Renal Outcome: A Systematic Review and Meta-Analysis of Clinical Studies. , 2021, 31, 5-20.		19
146	Mass Disasters and Burnout in Nephrology Personnel. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 829-837.	4.3	22
147	Nephrology in Spain. , 2021, , 639-655.		1
148	Albuminuria as a risk factor for mild cognitive impairment and dementiaâ€”what is the evidence?. Nephrology Dialysis Transplantation, 2021, 37, ii55-ii62.	0.7	17
149	Belimumab in Lupus Nephritis. New England Journal of Medicine, 2021, 384, 187-188.	29.6	2
150	Key unsolved issues in kidney replacement therapy. Journal of Internal Medicine, 2021, 290, 749-751.	6.1	0
151	Undiagnosed cardiovascular risk factors in overweight and obese individuals: a low income country experience. PeerJ, 2021, 9, e10870.	2.0	3
152	Iohexol plasma clearance simplified by Dried Blood Spot (DBS) sampling to measure renal function in conscious mice. Scientific Reports, 2021, 11, 4591.	3.4	9
153	Dynamic assessment of interleukinâ€6 during hemodialysis and mortality in coronavirus diseaseâ€19. Therapeutic Apheresis and Dialysis, 2021, 25, 908-916.	0.9	16
154	Urinary Cyclophilin A as Marker of Tubular Cell Death and Kidney Injury. Biomedicines, 2021, 9, 217.	3.2	12
155	Estimated GFR Slope in Kidney Transplant Patients. Transplantation, 2021, Publish Ahead of Print, .	1.0	4
156	Chloroquine may induce endothelial injury through lysosomal dysfunction and oxidative stress. Toxicology and Applied Pharmacology, 2021, 414, 115412.	2.9	21
157	Genetic kidney diseases as an underrecognized cause of chronic kidney disease: the key role of international registry reports. CKJ: Clinical Kidney Journal, 2021, 14, 1879-1885.	2.7	40
158	Role of Klotho in the Development of Essential Hypertension. Hypertension, 2021, 77, 740-750.	4.9	58
159	Kidneys also speak Spanish. Nefrologia, 2021, 41, 224-226.	0.4	1
160	<sc>TWEAKâ€14</sc> as a common pathway in the heart and the kidneys in cardiorenal syndrome. Journal of Pathology, 2021, 254, 5-19.	4.4	8
161	Predictors of outcome in a Spanish cohort of patients with Fabry disease on enzyme replacement therapy. Nefrologia, 2021, 41, 652-660.	0.6	4
162	Blood pressure monitoring in kidney transplantation: a systematic review on hypertension and target organ damage. Nephrology Dialysis Transplantation, 2021, 36, 1326-1346.	0.7	19

#	ARTICLE	IF	CITATIONS
163	The need for a cardioneurology subspecialty. CKJ: Clinical Kidney Journal, 2021, 14, 1491-1494.	2.7	12
164	Urinary Growth Differentiation Factor-15 (GDF15) levels as a biomarker of adverse outcomes and biopsy findings in chronic kidney disease. Journal of Nephrology, 2021, 34, 1819-1832.	2.1	26
165	Phosphate, Microbiota and CKD. Nutrients, 2021, 13, 1273.	4.1	25
166	Constitutive model of steel fiber reinforced concrete by coupling the fiber inclining and spacing effect. Construction and Building Materials, 2021, 280, 122423.	7.1	21
167	The Role of Epigenetics in the Progression of Clear Cell Renal Cell Carcinoma and the Basis for Future Epigenetic Treatments. Cancers, 2021, 13, 2071.	3.8	26
168	Immunological selection and monitoring of patients undergoing pig kidney transplantation. Xenotransplantation, 2021, 28, e12686.	3.0	12
169	Data Sharing Under the General Data Protection Regulation. Hypertension, 2021, 77, 1029-1035.	4.9	59
170	Deep Learning versus Spectral Techniques for Frequency Estimation of Single Tones: Reduced Complexity for Software-Defined Radio and IoT Sensor Communications. Sensors, 2021, 21, 2729.	3.9	8
171	Hypertension in kidney transplantation: a consensus statement of the "hypertension and the kidney" working group of the European Society of Hypertension. Journal of Hypertension, 2021, 39, 1513-1521.	0.5	20
172	Mitochondrion-driven nephroprotective mechanisms of novel glucose lowering medications. Mitochondrion, 2021, 58, 72-82.	3.5	13
173	Interleukina-17A: posible mediador y diana terapéutica en la hipertensión. Nefrología, 2021, 41, 244-257.	0.6	5
174	Interleukin-17A: Potential mediator and therapeutic target in hypertension. Nefrología, 2021, 41, 244-257.	0.4	7
175	Glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors for diabetes after solid organ transplantation. Transplant International, 2021, 34, 1341-1359.	1.7	12
176	Circular RNAs regulate cancer-related signaling pathways and serve as potential diagnostic biomarkers for human cancers. Cancer Cell International, 2021, 21, 317.	4.2	16
177	Renin-angiotensin system and inflammation update. Molecular and Cellular Endocrinology, 2021, 529, 111254.	3.2	57
178	Renin-Angiotensin System Blockers and the Risk of COVID-19-Related Mortality in Patients with Kidney Failure. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 1061-1072.	4.3	7
179	TWEAK Signaling Pathway Blockade Slows Cyst Growth and Disease Progression in Autosomal Dominant Polycystic Kidney Disease. Journal of the American Society of Nephrology: JASN, 2021, 32, 1913-1932.	0.5	21
180	Acute Kidney Injury is Aggravated in Aged Mice by the Exacerbation of Proinflammatory Processes. Frontiers in Pharmacology, 2021, 12, 662020.	3.6	21

#	ARTICLE	IF	CITATIONS
181	A multicenter blinded preclinical randomized controlled trial on Jak1/2 inhibition in MRL/MpJ-Fas mice with proliferative lupus nephritis predicts low effect size. <i>Kidney International</i> , 2021, 99, 1331-1341.	5.3	13
182	Developing the subspecialty of cardio-nephrology: The time has come. A position paper from the coordinating committee from the Working Group for Cardiorenal Medicine of the Spanish Society of Nephrology. <i>Nefrologia</i> , 2021, 41, 391-402.	0.6	3
183	Hyperkalemia in Chronic Kidney Disease in the New Era of Kidney Protection Therapies. <i>Drugs</i> , 2021, 81, 1467-1489.	10.8	30
184	Role of Macrophages and Related Cytokines in Kidney Disease. <i>Frontiers in Medicine</i> , 2021, 8, 688060.	2.6	51
185	Milestones of Precision Medicine: An Innovative, Multidisciplinary Overview. <i>Molecular Diagnosis and Therapy</i> , 2021, 25, 563-576.	3.7	7
186	Tasa de ultrafiltraci3n horaria ajustada a peso corporal y mortalidad en hemodi4lisis. <i>Nefrologia</i> , 2021, 41, 426-435.	0.6	4
187	Aguascalientes: one of the hottest chronic kidney disease (CKD) hotspots in Mexico and a CKD of unknown aetiology mystery to be solved. <i>CKJ: Clinical Kidney Journal</i> , 2021, 14, 2285-2294.	2.7	12
188	<sc>Sodium-glucose</sc> cotransporter 2 inhibitors for diabetes mellitus control after kidney transplantation: Review of the current evidence. <i>Nephrology</i> , 2021, 26, 1007-1017.	1.6	12
189	Differential effects of the second SARS-CoV-2 mRNA vaccine dose on T4cell immunity in naive and COVID-19 recovered individuals. <i>Cell Reports</i> , 2021, 36, 109570.	6.2	87
190	Guillain-Barre syndrome is a definite complication of SARS-CoV-2. <i>Annals of Medicine and Surgery</i> , 2021, 72, 102800.	1.1	0
191	The Role of Vascular Lesions in Diabetes Across a Spectrum of Clinical Kidney Disease. <i>Kidney International Reports</i> , 2021, 6, 2392-2403.	0.8	9
192	Verinurad/Febuxostat and Nephrotoxicity. <i>American Journal of Kidney Diseases</i> , 2021, 78, 468.	1.9	4
193	Nicotinamide and acute kidney injury. <i>CKJ: Clinical Kidney Journal</i> , 2021, 14, 2453-2462.	2.7	16
194	Substitution of Sugar-Sweetened Beverages for Other Beverages: Can It Be the Next Step Towards Healthy Aging?. <i>Current Nutrition Reports</i> , 2021, 10, 399-412.	4.4	5
195	Pharmacologic and interventional paradigms of diuretic resistance in congestive heart failure: a narrative review. <i>International Urology and Nephrology</i> , 2021, 53, 1839-1849.	1.4	6
196	Cognitive disorders in patients with chronic kidney disease: specificities of clinical assessment. <i>Nephrology Dialysis Transplantation</i> , 2021, 37, ii23-ii32.	0.7	32
197	Therapeutic implications of shared mechanisms in non-alcoholic fatty liver disease and chronic kidney disease. <i>Journal of Nephrology</i> , 2021, 34, 649-659.	2.1	13
198	Protective Role of Nrf2 in Renal Disease. <i>Antioxidants</i> , 2021, 10, 39.	5.1	53

#	ARTICLE	IF	CITATIONS
199	Neuropeptide Y as a risk factor for cardiorenal disease and cognitive dysfunction in chronic kidney disease: translational opportunities and challenges. <i>Nephrology Dialysis Transplantation</i> , 2021, 37, ii14-ii23.	0.7	12
200	The renal patient seen by non-renal physicians: the kidney embedded in the "milieu intérieur". <i>CKJ: Clinical Kidney Journal</i> , 2021, 14, 1077-1087.	2.7	1
201	European East-West divide in kidney disease: the need to understand the drivers of chronic kidney disease outcomes. <i>CKJ: Clinical Kidney Journal</i> , 2021, 14, 1-4.	2.7	7
202	Present and future of CONNECT: a new and compelling project of modern medicine. <i>Nephrology Dialysis Transplantation</i> , 2021, 37, ii1-ii3.	0.7	0
203	Atrasentan: The Difficult Task of Integrating Endothelin A Receptor Antagonists into Current Treatment Paradigm for Diabetic Kidney Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021, 16, 1775-1778.	4.3	4
204	Developing the subspecialty of cardio-nephrology: The time has come. A position paper from the coordinating committee from the Working Group for Cardiorenal Medicine of the Spanish Society of Nephrology. <i>Nefrologia</i> , 2021, 41, 391-402.	0.4	4
205	Predictors of outcome in a Spanish cohort of patients with Fabry disease on enzyme replacement therapy. <i>Nefrologia</i> , 2021, 41, 652-660.	0.4	2
206	Machine learning analysis of serum biomarkers for cardiovascular risk assessment in chronic kidney disease. <i>CKJ: Clinical Kidney Journal</i> , 2020, 13, 631-639.	2.7	5
207	SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 1452-1452.	0.7	0
208	Klotho, the elusive kidney-derived anti-ageing factor. <i>CKJ: Clinical Kidney Journal</i> , 2020, 13, 125-127.	2.7	24
209	SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 1825-1825.	0.7	7
210	Loss of NLRP6 expression increases the severity of acute kidney injury. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 587-598.	0.7	28
211	Choice of endpoint in kidney outcome trials: considerations from the EMPA-REG OUTCOME® trial. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 2103-2111.	0.7	22
212	A sudden decrease in serum creatinine and estimated glomerular filtration rate: clinical implications of administrative gender assignment in transgender persons. <i>CKJ: Clinical Kidney Journal</i> , 2020, 13, 1107-1108.	2.7	3
213	Aliskiren and the dual complement inhibition concept. <i>CKJ: Clinical Kidney Journal</i> , 2020, 13, 35-38.	2.7	7
214	The risk for urinary tract infections with sodium-glucose cotransporter 2 inhibitors: no longer a cause of concern?. <i>CKJ: Clinical Kidney Journal</i> , 2020, 13, 24-26.	2.7	22
215	Design and optimization strategies for the development of new drugs that treat chronic kidney disease. <i>Expert Opinion on Drug Discovery</i> , 2020, 15, 101-115.	5.1	13
216	Is there enough focus on lipophilicity in drug discovery?. <i>Expert Opinion on Drug Discovery</i> , 2020, 15, 261-263.	5.1	73

#	ARTICLE	IF	CITATIONS
217	Urinary transferrin pre-emptively identifies the risk of renal damage posed by subclinical tubular alterations. <i>Biomedicine and Pharmacotherapy</i> , 2020, 121, 109684.	5.7	25
218	A relook at how we assess tumor margins: Is it "TIME"™ for new criteria?. <i>Oral Oncology</i> , 2020, 111, 104980.	1.8	6
219	SGLT2 inhibitors for non-diabetic kidney disease: drugs to treat CKD that also improve glycaemia. <i>CKJ: Clinical Kidney Journal</i> , 2020, 13, 728-733.	2.7	73
220	Ckj consolidation among Q1 Urology and Nephrology journals. <i>CKJ: Clinical Kidney Journal</i> , 2020, 13, 723-727.	2.7	2
221	Complement and protection from tissue injury in COVID-19. <i>CKJ: Clinical Kidney Journal</i> , 2020, 13, 734-738.	2.7	4
222	An update review of intradialytic hypotension: concept, risk factors, clinical implications and management. <i>CKJ: Clinical Kidney Journal</i> , 2020, 13, 981-993.	2.7	101
223	Tacrolimus Prevents TWEAK-Induced PLA2R Expression in Cultured Human Podocytes. <i>Journal of Clinical Medicine</i> , 2020, 9, 2178.	2.5	9
224	Low Intracellular Water, Overhydration, and Mortality in Hemodialysis Patients. <i>Journal of Clinical Medicine</i> , 2020, 9, 3616.	2.5	14
225	Lyso-Gb3 Increases $\alpha$ 2 $\beta$ 1 Integrin Gene Expression in Cultured Human Podocytes in Fabry Nephropathy. <i>Journal of Clinical Medicine</i> , 2020, 9, 3659.	2.5	11
226	Givosiran for Acute Intermittent Porphyria. <i>New England Journal of Medicine</i> , 2020, 383, 1989-1990.	29.6	12
227	Megalyn/lipoprotein receptor-related protein 2 autoimmunity and kidney disease. <i>CKJ: Clinical Kidney Journal</i> , 2020, 13, 281-286.	2.7	6
228	Kidney disease and electrolytes in COVID-19: more than meets the eye. <i>CKJ: Clinical Kidney Journal</i> , 2020, 13, 274-280.	2.7	39
229	Hematuria Is Associated with More Severe Acute Tubulointerstitial Nephritis. <i>Journal of Clinical Medicine</i> , 2020, 9, 2135.	2.5	4
230	The Spectrum of Clinical and Serological Features of COVID-19 in Urban Hemodialysis Patients. <i>Journal of Clinical Medicine</i> , 2020, 9, 2264.	2.5	21
231	Diabetes mellitus in chronic kidney disease: Biomarkers beyond HbA1c to estimate glycemic control and diabetes-dependent morbidity and mortality. <i>Journal of Diabetes and Its Complications</i> , 2020, 34, 107707.	2.4	25
232	P134...A preclinical double-blinded, randomized, controlled, multicenter trial (pRCT) on Jak1/Jak2 inhibition in lupus nephritis. <i>Lupus Science and Medicine</i> , 2020, , .	2.8	0
233	A Simplified Iohexol-Based Method to Measure Renal Function in Sheep Models of Renal Disease. <i>Biology</i> , 2020, 9, 259.	2.9	3
234	Often forgotten, transport modality to dialysis may be life-saving. <i>CKJ: Clinical Kidney Journal</i> , 2020, 13, 510-512.	2.7	13

#	ARTICLE	IF	CITATIONS
235	Hypertensive nephropathy: a major roadblock hindering the advance of precision nephrology. CKJ: Clinical Kidney Journal, 2020, 13, 504-509.	2.7	35
236	Sweet dreams: therapeutic insights, targeting imaging and physiologic evidence linking sleep, melatonin and diabetic nephropathy. CKJ: Clinical Kidney Journal, 2020, 13, 522-530.	2.7	7
237	Newborn Congenital Abnormalities and Inflammatory Bowel Disease: Unveiling an Unexplored Relationship. Journal of Crohn's and Colitis, 2020, 14, 1033-1034.	1.2	0
238	Persistent Kidney Dysfunction after Acute Kidney Injury Predicts Short-Term Outpatient Mortality. Internal Medicine Journal, 2020, , .	0.9	4
239	Ferroptosis and kidney disease. Nefrologia, 2020, 40, 384-394.	0.4	16
240	Improvement of gastrointestinal symptoms in a significant proportion of male patients with classic Fabry disease treated with agalsidase beta: A Fabry Registry analysis stratified by phenotype. Molecular Genetics and Metabolism Reports, 2020, 25, 100670.	1.1	8
241	Impacto de la pandemia COVID-19 en los servicios de Nefrología en España. Nefrologia, 2020, 40, 579-584.	0.6	18
242	Gender, Albuminuria and Chronic Kidney Disease Progression in Treated Diabetic Kidney Disease. Journal of Clinical Medicine, 2020, 9, 1611.	2.5	15
243	Epigenetic Modifiers as Potential Therapeutic Targets in Diabetic Kidney Disease. International Journal of Molecular Sciences, 2020, 21, 4113.	4.1	47
244	Blood pressure targets in patients with chronic kidney disease: MDRD and AASK now confirming SPRINT. CKJ: Clinical Kidney Journal, 2020, 13, 287-290.	2.7	5
245	<sc>PDGFR</sc> and kidney fibrosis. EMBO Molecular Medicine, 2020, 12, e11729.	6.8	8
246	SGLT2i and postglomerular vasodilation. Kidney International, 2020, 97, 805-806.	5.3	4
247	Chronodisruption: A Poorly Recognized Feature of CKD. Toxins, 2020, 12, 151.	3.4	19
248	Exploring Sodium Glucose Co-Transporter-2 (SGLT2) Inhibitors for Organ Protection in COVID-19. Journal of Clinical Medicine, 2020, 9, 2030.	2.5	28
249	Ferroptosis and kidney disease. Nefrologia, 2020, 40, 384-394.	0.6	50
250	TRAF3 Modulation: Novel Mechanism for the Anti-inflammatory Effects of the Vitamin D Receptor Agonist Paricalcitol in Renal Disease. Journal of the American Society of Nephrology: JASN, 2020, 31, 2026-2042.	0.5	10
251	Effective Nephroprotection Against Acute Kidney Injury with a Star-Shaped Polyglutamate-Curcuminoid Conjugate. Scientific Reports, 2020, 10, 2056.	3.4	26
252	The Role of PGC-1 $\alpha$ and Mitochondrial Biogenesis in Kidney Diseases. Biomolecules, 2020, 10, 347.	4.1	150

#	ARTICLE	IF	CITATIONS
253	Serum Levels and Removal by Haemodialysis and Haemodiafiltration of Tryptophan-Derived Uremic Toxins in ESKD Patients. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1522.	4.1	16
254	Cardiomyopathy and kidney function in agalsidase beta-treated female Fabry patients: a pre-treatment vs. post-treatment analysis. <i>ESC Heart Failure</i> , 2020, 7, 825-834.	3.0	15
255	Pelacarsen for lowering lipoprotein(a): implications for patients with chronic kidney disease. <i>CKJ: Clinical Kidney Journal</i> , 2020, 13, 753-757.	2.7	21
256	Molecular pathways driving omeprazole nephrotoxicity. <i>Redox Biology</i> , 2020, 32, 101464.	9.0	43
257	Targeting the progression of chronic kidney disease. <i>Nature Reviews Nephrology</i> , 2020, 16, 269-288.	9.3	505
258	Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY): a prospective observational study and embedded randomised placebo-controlled trial. <i>Lancet Diabetes and Endocrinology</i> , 2020, 8, 301-312.	11.1	177
259	Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet</i> , 2020, 395, 709-733.	11.9	3,341
260	Management of atrial fibrillation in patients with chronic kidney disease in clinical practice: a joint European Heart Rhythm Association (EHRA) and European Renal Association/European Dialysis and Transplantation Association (ERA/EDTA) physician-based survey. <i>Europace</i> , 2020, 22, 496-505.	1.6	30
261	Could IL-17A Be a Novel Therapeutic Target in Diabetic Nephropathy?. <i>Journal of Clinical Medicine</i> , 2020, 9, 272.	2.5	33
262	Serum osmolarity as a potential predictor for contrast-induced nephropathy following elective coronary angiography. <i>International Urology and Nephrology</i> , 2020, 52, 541-547.	1.4	4
263	Sodium-glucose cotransporter 2 inhibition: towards an indication to treat diabetic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, i13-i23.	0.7	27
264	Effect of Uric Acid-Lowering Agents on Cardiovascular Outcome in Patients With Heart Failure: A Systematic Review and Meta-Analysis of Clinical Studies. <i>Angiology</i> , 2020, 71, 315-323.	1.8	25
265	Albuminuria Downregulation of the Anti-Aging Factor Klotho: The Missing Link Potentially Explaining the Association of Pathological Albuminuria with Premature Death. <i>Advances in Therapy</i> , 2020, 37, 62-72.	2.9	31
266	The Contribution of Histone Crotonylation to Tissue Health and Disease: Focus on Kidney Health. <i>Frontiers in Pharmacology</i> , 2020, 11, 393.	3.6	24
267	Unraveling the Drivers and Consequences of Gut Microbiota Disruption in Fabry Disease: The lyso-Cb3 Link. <i>Future Microbiology</i> , 2020, 15, 227-231.	1.9	7
268	GLP-1 Receptor Agonists and Diabetic Kidney Disease: A Call of Attention to Nephrologists. <i>Journal of Clinical Medicine</i> , 2020, 9, 947.	2.5	91
269	Inflammation both increases and causes resistance to FGF23 in normal and uremic rats. <i>Clinical Science</i> , 2020, 134, 15-32.	4.2	22
270	Fabry disease and COVID-19: international expert recommendations for management based on real-world experience. <i>CKJ: Clinical Kidney Journal</i> , 2020, 13, 913-925.	2.7	11



#	ARTICLE	IF	CITATIONS
271	The unaccomplished mission of reducing mortality in patients on kidney replacement therapy. CKJ: Clinical Kidney Journal, 2020, 13, 948-951.	2.7	3
272	The dirty little secret of urate-lowering therapy: useless to stop chronic kidney disease progression and may increase mortality. CKJ: Clinical Kidney Journal, 2020, 13, 936-947.	2.7	13
273	IL-17A as a Potential Therapeutic Target for Patients on Peritoneal Dialysis. Biomolecules, 2020, 10, 1361.	4.1	14
274	Decomposition Study of Praseodymium Oxalate as a Precursor for Praseodymium Oxide in the Microwave Field. ACS Omega, 2020, 5, 21338-21344.	3.5	6
275	Impact of COVID-19 pandemic in Spanish Nephrology Services. Nefrologia, 2020, 40, 579-584.	0.4	4
276	MYH9-related disease: it does exist, may be more frequent than you think and requires specific therapy. CKJ: Clinical Kidney Journal, 2019, 12, 488-493.	2.7	23
277	Lyso-Gb3 modulates the gut microbiota and decreases butyrate production. Scientific Reports, 2019, 9, 12010.	3.4	24
278	Atherosclerosis in Chronic Kidney Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2019, 39, 1938-1966.	3.9	185
279	ERT impact on left ventricular mass in Fabry disease. Molecular Genetics and Metabolism Reports, 2019, 20, 100485.	1.1	0
280	Renal hyperfiltration defined by high estimated glomerular filtration rate: A risk factor for cardiovascular disease and mortality. Diabetes, Obesity and Metabolism, 2019, 21, 2368-2383.	4.5	63
281	Nrf2 Plays a Protective Role Against Intravascular Hemolysis-Mediated Acute Kidney Injury. Frontiers in Pharmacology, 2019, 10, 740.	3.6	38
282	Dietary Care for ADPKD Patients: Current Status and Future Directions. Nutrients, 2019, 11, 1576.	4.1	27
283	Milk Fermented with Lactobacillus fermentum Ameliorates Indomethacin-Induced Intestinal Inflammation: An Exploratory Study. Nutrients, 2019, 11, 1610.	4.1	16
284	Dihydrogen Bond in the Aminoborane Complex of a Nicergoline Intermediate. Molecules, 2019, 24, 2548.	3.8	1
285	Mapping 123 million neonatal, infant and child deaths between 2000 and 2017. Nature, 2019, 574, 353-358.	35.3	175
286	The chaos of hypertension guidelines for chronic kidney disease patients. CKJ: Clinical Kidney Journal, 2019, 12, 771-777.	2.7	11
287	A journey from microenvironment to macroenvironment: the role of metaflammation and epigenetic changes in cardiorenal disease. CKJ: Clinical Kidney Journal, 2019, 12, 861-870.	2.7	14
288	The role of endothelial glycocalyx in health and disease. CKJ: Clinical Kidney Journal, 2019, 12, 611-619.	2.7	80

#	ARTICLE	IF	CITATIONS
289	The Membership Committee of the ESC. Cardiovascular Research, 2019, 115, e130-e132.	3.6	0
290	USP11 acts as a histone deubiquitinase functioning in chromatin reorganization during DNA repair. Nucleic Acids Research, 2019, 47, 9721-9740.	13.8	55
291	Treatment of idiopathic membranous nephropathy in adults: KDIGO 2012, cyclophosphamide and cyclosporine A are out, rituximab is the new normal. CKJ: Clinical Kidney Journal, 2019, 12, 629-638.	2.7	28
292	Interleukin 17A Participates in Renal Inflammation Associated to Experimental and Human Hypertension. Frontiers in Pharmacology, 2019, 10, 1015.	3.6	40
293	Antidiuretic Hormone and Serum Osmolarity Physiology and Related Outcomes: What Is Old, What Is New, and What Is Unknown?. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 5406-5420.	3.5	31
294	Positive/retained SDHB immunostaining in renal cell carcinomas associated to germline SDHB-deficiency: case report. Diagnostic Pathology, 2019, 14, 42.	2.0	6
295	Translation of a standardized manufacturing protocol for mesenchymal stromal cells: A systematic comparison of validation and manufacturing data. Cytotherapy, 2019, 21, 468-482.	0.7	34
296	Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation and Study of Diabetic Nephropathy with Atrasentan: what was learned about the treatment of diabetic kidney disease with canagliflozin and atrasentan?. CKJ: Clinical Kidney Journal, 2019, 12, 313-321.	2.7	38
297	MAP3K kinases and kidney injury. Nefrologia, 2019, 39, 568-580.	0.6	23
298	Common core content in education for nurses in ambulance care in Sweden, Finland and Belgium. Nurse Education in Practice, 2019, 38, 34-39.	2.7	8
299	Diagnostic Utility of Exome Sequencing for Kidney Disease. New England Journal of Medicine, 2019, 380, 2078-2081.	29.6	22
300	Criteria for classification of proteinâ€“energy wasting in dialysis patients: impact on prevalence. British Journal of Nutrition, 2019, 121, 1271-1278.	2.6	23
301	Curcumin reduces renal damage associated with rhabdomyolysis by decreasing ferroptosisâ€“mediated cell death. FASEB Journal, 2019, 33, 8961-8975.	0.4	179
302	Questioning the Safety of Calcidiol in Hemodialysis Patients. Nutrients, 2019, 11, 959.	4.1	2
303	PGCâ€“1â€“ deficiency causes spontaneous kidney inflammation and increases the severity of nephrotoxic AKI. Journal of Pathology, 2019, 249, 65-78.	4.4	78
304	Pentoxifylline for Renal Protection in Diabetic Kidney Disease. A Model of Old Drugs for New Horizons. Journal of Clinical Medicine, 2019, 8, 287.	2.5	42
305	The new Clinical Kidney Journal, 4 years later. CKJ: Clinical Kidney Journal, 2019, 12, 1-5.	2.7	3
306	Pros and cons of antithrombotic therapy in end-stage kidney disease: a 2019 update. Nephrology Dialysis Transplantation, 2019, 34, 923-933.	0.7	24

#	ARTICLE	IF	CITATIONS
307	The Spanish Society of Nephrology (SENEFRO) commentary to the Spain GBD 2016 report: Keeping chronic kidney disease out of sight of health authorities will only magnify the problem. <i>Nefrologia</i> , 2019, 39, 29-34.	0.4	17
308	Burden, access and disparities in kidney disease: chronic kidney disease hotspots and progress one step at a time. <i>CKJ: Clinical Kidney Journal</i> , 2019, 12, 157-159.	2.7	4
309	Clarifying the concept of chronic kidney disease for non-nephrologists. <i>CKJ: Clinical Kidney Journal</i> , 2019, 12, 258-261.	2.7	77
310	NIK as a Druggable Mediator of Tissue Injury. <i>Trends in Molecular Medicine</i> , 2019, 25, 341-360.	7.0	31
311	Surviving Acute Organ Failure: Cell Polyploidization and Progenitor Proliferation. <i>Trends in Molecular Medicine</i> , 2019, 25, 366-381.	7.0	65
312	SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 208-230.	0.7	150
313	Proteomics for Clinical Assessment of Kidney Disease. <i>Proteomics - Clinical Applications</i> , 2019, 13, e1900004.	1.9	3
314	Sarcopenia in CKD: a roadmap from basic pathogenetic mechanisms to clinical trials. <i>CKJ: Clinical Kidney Journal</i> , 2019, 12, 110-112.	2.7	31
315	Comparing outcomes of biopsy-proven anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis patients treated with cyclophosphamide in the 20th and 21st centuries: a 23-year study. <i>CKJ: Clinical Kidney Journal</i> , 2019, 12, 42-48.	2.7	3
316	MAP3K kinases and kidney injury. <i>Nefrologia</i> , 2019, 39, 568-580.	0.4	7
317	Serpiginous-like choroiditis as sign of intraocular tuberculosis. <i>Journal Francais D'Ophtalmologie</i> , 2019, 42, 932-934.	0.4	2
318	The Spanish Society of Nephrology (SENEFRO) commentary to the Spain GBD 2016 report: Keeping chronic kidney disease out of sight of health authorities will only magnify the problem. <i>Nefrologia</i> , 2019, 39, 29-34.	0.6	62
319	Household Transmission of Seasonal Influenza From HIV-Infected and HIV-Uninfected Individuals in South Africa, 2013-2014. <i>Journal of Infectious Diseases</i> , 2019, 219, 1605-1615.	3.9	3
320	MAGE genes in the kidney: identification of MAGED2 as upregulated during kidney injury and in stressed tubular cells. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 1498-1507.	0.7	17
321	Characterization of single microvesicles in plasma from glioblastoma patients. <i>Neuro-Oncology</i> , 2019, 21, 606-615.	1.2	79
322	Multilayered Interplay Between Fructose and Salt in Development of Hypertension. <i>Hypertension</i> , 2019, 73, 265-272.	4.9	20
323	Air pollution and kidney disease: review of current evidence. <i>CKJ: Clinical Kidney Journal</i> , 2019, 12, 19-32.	2.7	82
324	Visualization and quantification of mitochondrial structure in the endothelium of intact arteries. <i>Cardiovascular Research</i> , 2019, 115, 1546-1556.	3.6	25

#	ARTICLE	IF	CITATIONS
325	Advances in understanding the role of angiotensin-regulated proteins in kidney diseases. Expert Review of Proteomics, 2019, 16, 77-92.	3.0	23
326	Obesity and chronic kidney disease progression—the role of a new adipocytokine: C1q/tumour necrosis factor-related protein-1. CKJ: Clinical Kidney Journal, 2019, 12, 420-426.	2.7	24
327	Potential Dangers of Serum Urate-Lowering Therapy. American Journal of Medicine, 2019, 132, 457-467.	1.4	42
328	Vaccination in the Adult Patient Infected with HIV: A Review of Vaccine Efficacy and Immunogenicity. American Journal of Medicine, 2019, 132, 437-446.	1.4	40
329	Working towards novel albuminuria endpoints in chronic kidney disease. Lancet Diabetes and Endocrinology, 2019, 7, 80-82.	11.1	1
330	The effect of chronic kidney disease on lipid metabolism. International Urology and Nephrology, 2019, 51, 265-277.	1.4	35
331	The large protein of Peste-des-petits-ruminants virus exhibits RNA triphosphatase activity, the first enzyme in mRNA capping pathway. Virus Genes, 2019, 55, 68-75.	1.8	7
332	Urine proteomic profiling in patients with nephrolithiasis and cystinuria. International Urology and Nephrology, 2019, 51, 593-599.	1.4	11
333	The effect of enzyme replacement therapy on clinical outcomes in female patients with Fabry disease – A systematic literature review by a European panel of experts. Molecular Genetics and Metabolism, 2019, 126, 224-235.	2.1	67
334	Podocyturia: why it may have added value in rare diseases. CKJ: Clinical Kidney Journal, 2019, 12, 49-52.	2.7	12
335	A Low-Cost Pupil Center Localization Algorithm Based on Maximized Integral Voting of Circular Hollow Kernels. Computer Journal, 2019, 62, 1001-1015.	2.3	3
336	Expanding congenital abnormalities of the kidney and urinary tract (CAKUT) genetics: basonuclein 2 (BNC2) and lower urinary tract obstruction. Annals of Translational Medicine, 2019, 7, S226-S226.	1.6	2
337	Clinical glycomics in the diagnostic laboratory. Annals of Translational Medicine, 2019, 7, S220-S220.	1.6	7
338	Association of FGF-2 Concentrations with Atheroma Progression in Chronic Kidney Disease Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2018, 13, 577-584.	4.3	13
339	Phenytoin inhibits necroptosis. Cell Death and Disease, 2018, 9, 359.	6.3	55
340	Nephrotoxicity. , 2018, , 169-184.		2
341	Fabry disease revisited: Management and treatment recommendations for adult patients. Molecular Genetics and Metabolism, 2018, 123, 416-427.	2.1	431
342	Factors associating with differences in the incidence of renal replacement therapy among elderly: data from the ERA-EDTA Registry. Nephrology Dialysis Transplantation, 2018, 33, 1428-1435.	0.7	8

#	ARTICLE	IF	CITATIONS
343	Phenotypic characteristics of the p.Asn215Ser (p.N215S) <i>G</i> mutation in male and female patients with Fabry disease: A multicenter Fabry Registry study. <i>Molecular Genetics &amp; Genomic Medicine</i> , 2018, 6, 492-503.	1.3	79
344	CKD. , 2018, , 319-326.		0
345	Cell death-based approaches in treatment of the urinary tract-associated diseases: a fight for survival in the killing fields. <i>Cell Death and Disease</i> , 2018, 9, 118.	6.3	25
346	Albumin downregulates Klotho in tubular cells. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, 1712-1722.	0.7	82
347	Paricalcitol and albuminuria: tread carefully. <i>Lancet Diabetes and Endocrinology</i> ,the, 2018, 6, 3-5.	11.1	7
348	Lipid Management in Chronic Kidney Disease: Systematic Review of PCSK9 Targeting. <i>Drugs</i> , 2018, 78, 215-229.	10.8	33
349	Gremlin activates the Notch pathway linked to renal inflammation. <i>Clinical Science</i> , 2018, 132, 1097-1115.	4.2	31
350	Enzyme replacement therapy dose and Fabry nephropathy. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, 1284-1289.	0.7	7
351	Bone, inflammation and the bone marrow niche in chronic kidney disease: what do we know?. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, 2092-2100.	0.7	27
352	Effectiveness of a Chlorhexidine Dressing on Silver-coated External Ventricular Drain-associated Colonization and Infection: A Prospective Single-blinded Randomized Controlled Clinical Trial. <i>Clinical Infectious Diseases</i> , 2018, 67, 1868-1877.	5.6	17
353	Increased urinary osmolyte excretion indicates chronic kidney disease severity and progression rate. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, 2156-2164.	0.7	47
354	Targeting of regulated necrosis in kidney disease. <i>Nefrologia</i> , 2018, 38, 125-135.	0.4	18
355	TWEAK and RIPK1 mediate a second wave of cell death during AKI. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 4182-4187.	7.4	113
356	Targeting epigenetic DNA and histone modifications to treat kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, 1875-1886.	0.7	96
357	Targeting of regulated necrosis in kidney disease. <i>Nefrologia</i> , 2018, 38, 125-135.	0.6	37
358	Connective tissue growth factor induces renal fibrosis via epidermal growth factor receptor activation. <i>Journal of Pathology</i> , 2018, 244, 227-241.	4.4	53
359	Bisphenol A is an exogenous toxin that promotes mitochondrial injury and death in tubular cells. <i>Environmental Toxicology</i> , 2018, 33, 325-332.	4.0	53
360	Bleeding in advanced CKD patients on antithrombotic medication – A critical appraisal. <i>Pharmacological Research</i> , 2018, 129, 535-543.	7.1	17

#	ARTICLE	IF	CITATIONS
361	Global, regional, and national age-sex-specific mortality and life expectancy, 1950â€“2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet, The</i> , 2018, 392, 1684-1735.	11.9	813
362	Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980â€“2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet, The</i> , 2018, 392, 1736-1788.	11.9	5,415
363	Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990â€“2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet, The</i> , 2018, 392, 1923-1994.	11.9	3,512
364	Population and fertility by age and sex for 195 countries and territories, 1950â€“2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet, The</i> , 2018, 392, 1995-2051.	11.9	313
365	Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990â€“2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet, The</i> , 2018, 392, 1789-1858.	11.9	9,267
366	Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet, The</i> , 2018, 392, 2091-2138.	11.9	357
367	Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990â€“2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet, The</i> , 2018, 392, 1859-1922.	11.9	2,298
368	Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. <i>Journal of Extracellular Vesicles</i> , 2018, 7, 1535750.	12.2	7,596
369	Unravelling drug-induced hypertension: molecular mechanisms of aldosterone-independent mineralocorticoid receptor activation by posaconazole. <i>CKJ: Clinical Kidney Journal</i> , 2018, 11, 688-690.	2.7	7
370	Higher Proportion of Non-1-84 PTH Fragments in Peritoneal Dialysis Patients Compared to Hemodialysis Patients Using Solutions Containing 1.75 mmol/l Calcium. <i>Frontiers in Physiology</i> , 2018, 9, 1643.	2.8	3
371	Gremlin Regulates Tubular Epithelial to Mesenchymal Transition via VEGFR2: Potential Role in Renal Fibrosis. <i>Frontiers in Pharmacology</i> , 2018, 9, 1195.	3.6	31
372	Lipid management in patients with chronic kidney disease. <i>Nature Reviews Nephrology</i> , 2018, 14, 727-749.	9.3	163
373	Novel Urinary Biomarkers For Improved Prediction Of Progressive eGFR Loss In Early Chronic Kidney Disease Stages And In High Risk Individuals Without Chronic Kidney Disease. <i>Scientific Reports</i> , 2018, 8, 15940.	3.4	56
374	Practical issues in clinical scenarios involving CKD patients requiring antithrombotic therapy in light of the 2017 ESC guideline recommendations. <i>BMC Medicine</i> , 2018, 16, 158.	5.6	16
375	Women and renal replacement therapy in Europe: lower incidence, equal access to transplantation, longer survival than men. <i>CKJ: Clinical Kidney Journal</i> , 2018, 11, 1-6.	2.7	26
376	Measuring performance on the Healthcare Access and Quality Index for 195 countries and territories and selected subnational locations: a systematic analysis from the Global Burden of Disease Study 2016. <i>Lancet, The</i> , 2018, 391, 2236-2271.	11.9	678
377	20-HETE. <i>Hypertension</i> , 2018, 72, 12-18.	4.9	52
378	Salt Intake and Immunity. <i>Hypertension</i> , 2018, 72, 19-23.	4.9	40

#	ARTICLE	IF	CITATIONS
379	Case of Refractory Hypertension Controlled After Aortic and Mitral Valve Replacement and Coronary Artery Bypass Grafting. Hypertension, 2018, 72, 3-9.	4.9	0
380	Capillary rarefaction from the kidney point of view. CKJ: Clinical Kidney Journal, 2018, 11, 295-301.	2.7	55
381	Extended Corona Product as an Exactly Tractable Model for Weighted Heterogeneous Networks. Computer Journal, 2018, 61, 745-760.	2.3	20
382	The Future of IL-1 Targeting in Kidney Disease. Drugs, 2018, 78, 1073-1083.	10.8	20
383	Impact of Altered Intestinal Microbiota on Chronic Kidney Disease Progression. Toxins, 2018, 10, 300.	3.4	110
384	Deleting Death and Dialysis: Conservative Care of Cardio-Vascular Risk and Kidney Function Loss in Chronic Kidney Disease (CKD). Toxins, 2018, 10, 237.	3.4	31
385	Identification and Chemical Characterization of Insoluble Contaminants in Hemodialysis Water Treatment. Water (Switzerland), 2018, 10, 486.	2.8	2
386	CCL20 blockade increases the severity of nephrotoxic folic acid-induced acute kidney injury. Journal of Pathology, 2018, 246, 191-204.	4.4	28
387	La carga de enfermedad en España: resultados del Estudio de la Carga Global de las Enfermedades 2016. Medicina Clínica, 2018, 151, 171-190.	0.6	122
388	Magnetic resonance imaging biomarkers for chronic kidney disease: a position paper from the European Cooperation in Science and Technology Action PARENCHIMA. Nephrology Dialysis Transplantation, 2018, 33, ii4-ii14.	0.7	99
389	Research update for articles published in <sc>EJCI</sc> in 2016. European Journal of Clinical Investigation, 2018, 48, e13016.	3.4	0
390	Meso-American nephropathy: what we have learned about the potential genetic influence on chronic kidney disease development*. CKJ: Clinical Kidney Journal, 2018, 11, 491-495.	2.7	21
391	Effects of Pentoxifylline on Soluble Klotho Concentrations and Renal Tubular Cell Expression in Diabetic Kidney Disease. Diabetes Care, 2018, 41, 1817-1820.	9.0	62
392	European expert consensus statement on therapeutic goals in Fabry disease. Molecular Genetics and Metabolism, 2018, 124, 189-203.	2.1	133
393	Influence of dialysis membrane composition on plasma bisphenol A levels during online hemodiafiltration. PLoS ONE, 2018, 13, e0193288.	2.5	21
394	Aspirin for Primary Prevention of Cardiovascular Disease and Renal Disease Progression in Chronic Kidney Disease Patients: a Multicenter Randomized Clinical Trial (AASER Study). Cardiovascular Drugs and Therapy, 2018, 32, 255-263.	2.8	47
395	TWEAK increases CD74 expression and sensitizes to DDT proinflammatory actions in tubular cells. PLoS ONE, 2018, 13, e0199391.	2.5	13
396	Clinical characteristics and prognostic significance of EBER positivity in diffuse large B-cell lymphoma: A meta-analysis. PLoS ONE, 2018, 13, e0199398.	2.5	25

#	ARTICLE	IF	CITATIONS
397	Podocytes are new cellular targets of haemoglobin-mediated renal damage. <i>Journal of Pathology</i> , 2018, 244, 296-310.	4.4	54
398	Age-adjusted Charlson Comorbidity Index as a prognostic factor for radical prostatectomy outcomes of very high-risk prostate cancer patients. <i>PLoS ONE</i> , 2018, 13, e0199365.	2.5	16
399	Noninvasive diagnosis of chronic kidney diseases using urinary proteome analysis. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, gfw337.	0.7	63
400	Ferroptosis, but Not Necroptosis, Is Important in Nephrotoxic Folic Acid-Induced AKI. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 218-229.	0.5	393
401	Diagnóstico y tratamiento de la enfermedad de Fabry. <i>Medicina Clínica</i> , 2017, 148, 132-138.	0.6	21
402	Deferasirox-induced iron depletion promotes BclxL downregulation and death of proximal tubular cells. <i>Scientific Reports</i> , 2017, 7, 41510.	3.4	27
403	Hypertension in dialysis patients: a consensus document by the European Renal and Cardiovascular Medicine (EURECA-m) working group of the European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) and the Hypertension and the Kidney working group of the European Society of Hypertension (ESH)*. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, 620-640.	0.7	141
404	Global Cardiovascular and Renal Outcomes of Reduced GFR. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 2167-2179.	0.5	205
405	The systemic nature of CKD. <i>Nature Reviews Nephrology</i> , 2017, 13, 344-358.	9.3	294
406	Hypertension in dialysis patients. <i>Journal of Hypertension</i> , 2017, 35, 657-676.	0.5	58
407	Guía de práctica clínica sobre el diagnóstico y tratamiento de la hiponatremia. <i>Nefrología</i> , 2017, 37, 370-380.	0.6	18
408	Healthcare Access and Quality Index based on mortality from causes amenable to personal health care in 195 countries and territories, 1990-2015: a novel analysis from the Global Burden of Disease Study 2015. <i>Lancet, The</i> , 2017, 390, 231-266.	11.9	511
409	Improvement of Fabry Disease-Related Gastrointestinal Symptoms in a Significant Proportion of Female Patients Treated with Agalsidase Beta: Data from the Fabry Registry. <i>JIMD Reports</i> , 2017, 38, 45-51.	1.2	19
410	How to harness the private sector for universal health coverage. <i>Lancet, The</i> , 2017, 390, e19-e20.	11.9	12
411	The quest for equilibrium: exploring the thin red line between bleeding and ischaemic risks in the management of acute coronary syndromes in chronic kidney disease patients. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, 1967-1976.	0.7	14
412	Child and Adolescent Health From 1990 to 2015. <i>JAMA Pediatrics</i> , 2017, 171, 573.	6.1	321
413	Diagnosis and treatment of Fabry disease. <i>Medicina Clínica (English Edition)</i> , 2017, 148, 132-138.	0.2	2
414	Familial hematuria: A review. <i>Medicina (Lithuania)</i> , 2017, 53, 1-10.	2.0	23



#	ARTICLE	IF	CITATIONS
415	Tweak up-regulates endothelin-1 system in mouse and human endothelial cells. Cardiovascular Research, 2017, 113, 207-221.	3.6	23
416	Screening, diagnosis, and management of patients with Fabry disease: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference. Kidney International, 2017, 91, 284-293.	5.3	127
417	Urine metabolomics insight into acute kidney injury point to oxidative stress disruptions in energy generation and H2S availability. Journal of Molecular Medicine, 2017, 95, 1399-1409.	4.0	30
418	Low dose aspirin increases 15-epi-lipoxin A4 levels in diabetic chronic kidney disease patients. Prostaglandins Leukotrienes and Essential Fatty Acids, 2017, 125, 8-13.	2.3	18
419	Global, regional, and national under-5 mortality, adult mortality, age-specific mortality, and life expectancy, 1970"2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet, The, 2017, 390, 1084-1150.	11.9	594
420	Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990"2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet, The, 2017, 390, 1260-1344.	11.9	1,647
421	Global, regional, and national age-sex specific mortality for 264 causes of death, 1980"2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet, The, 2017, 390, 1151-1210.	11.9	3,733
422	Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990"2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet, The, 2017, 390, 1211-1259.	11.9	5,921
423	Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990"2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet, The, 2017, 390, 1345-1422.	11.9	1,969
424	Measuring progress and projecting attainment on the basis of past trends of the health-related Sustainable Development Goals in 188 countries: an analysis from the Global Burden of Disease Study 2016. Lancet, The, 2017, 390, 1423-1459.	11.9	289
425	Exantema generalizado y linfocitosis como presentaci3n cl3nica de leucemia/linfoma T del adulto. Medicina Cl3nica, 2017, 149, e37.	0.6	0
426	Association of kidney fibrosis with urinary peptides: a path towards non-invasive liquid biopsies?. Scientific Reports, 2017, 7, 16915.	3.4	69
427	Resistant Hypertension in Elderly People with Chronic Kidney Disease. , 2017, , 183-193.		0
428	Bcl3: a regulator of NF-ÎB inducible by TWEAK in acute kidney injury with anti-inflammatory and antiapoptotic properties in tubular cells. Experimental and Molecular Medicine, 2017, 49, e352-e352.	7.6	46
429	Gu3a ERBP sobre la diabetes en la enfermedad renal cr3nica estadio 3B o mayor: 2metformina para todos?. Nefrologia, 2017, 37, 567-571.	0.6	8
430	Is Plasma Proteomics Able to Provide Alternative Paths to Better Understand Hypertension?. Hypertension, 2017, 70, 250-252.	4.9	1
431	Translational science in chronic kidney disease. Clinical Science, 2017, 131, 1617-1629.	4.2	17
432	Inhibition of Bromodomain and Extraterminal Domain Family Proteins Ameliorates Experimental Renal Damage. Journal of the American Society of Nephrology: JASN, 2017, 28, 504-519.	0.5	60

#	ARTICLE	IF	CITATIONS
433	TLR4-mediated inflammation is a key pathogenic event leading to kidney damage and fibrosis in cyclosporine nephrotoxicity. Archives of Toxicology, 2017, 91, 1925-1939.	4.2	75
434	<scp>MXRA</scp>5 is a <scp>TGF</scp>β1-regulated human protein with anti-inflammatory and anti-fibrotic properties. Journal of Cellular and Molecular Medicine, 2017, 21, 154-164.	3.5	67
435	Vascular Function and Uric Acid-Lowering in Stage 3 CKD. Journal of the American Society of Nephrology: JASN, 2017, 28, 943-952.	0.5	57
436	Mitogen-Activated Protein Kinase 14 Promotes AKI. Journal of the American Society of Nephrology: JASN, 2017, 28, 823-836.	0.5	41
437	Promising novel therapeutic approaches in the management of gastrointestinal stromal tumors. Future Oncology, 2017, 13, 185-194.	2.4	8
438	Implicit associative learning in synesthetes and nonsynesthetes. Psychonomic Bulletin and Review, 2017, 24, 935-943.	6.6	12
439	Lesinurad: what the nephrologist should know. CKJ: Clinical Kidney Journal, 2017, 10, 679-687.	2.7	30
440	Nutrients Turned into Toxins: Microbiota Modulation of Nutrient Properties in Chronic Kidney Disease. Nutrients, 2017, 9, 489.	4.1	82
441	Inflammatory Cytokines as Uremic Toxins: ¿Ni Son Todos Los Que Estan, Ni Estan Todos Los Que Son? Toxins, 2017, 9, 114.	3.4	62
442	2017 update on the relationship between diabetes and colorectal cancer: epidemiology, potential molecular mechanisms and therapeutic implications. Oncotarget, 2017, 8, 18456-18485.	2.0	142
443	Expression of uPAR in Urinary Podocytes of Patients with Fabry Disease. International Journal of Nephrology, 2017, 2017, 1-7.	1.4	8
444	Impact of post-dialysis calcium level on ex vivo rat aortic wall calcification. PLoS ONE, 2017, 12, e0183730.	2.5	9
445	Low lean tissue mass is an independent risk factor for mortality in patients with stages 4 and 5 non-dialysis chronic kidney disease. CKJ: Clinical Kidney Journal, 2017, 10, 170-175.	2.7	14
446	Clinical proteomics in kidney disease as an exponential technology: heading towards the disruptive phase. CKJ: Clinical Kidney Journal, 2017, 10, 188-191.	2.7	24
447	Does wealth make health? Cherchez la renal replacement therapy. CKJ: Clinical Kidney Journal, 2017, 10, 45-48.	2.7	3
448	Not all extracellular vesicles were created equal: clinical implications. Annals of Translational Medicine, 2017, 5, 111-111.	1.6	27
449	Colon cancer modulation by a diabetic environment: A single institutional experience. PLoS ONE, 2017, 12, e0172300.	2.5	6
450	Enzyme replacement therapy for Anderson-Fabry disease: A complementary overview of a Cochrane publication through a linear regression and a pooled analysis of proportions from cohort studies. PLoS ONE, 2017, 12, e0173358.	2.5	74

#	ARTICLE	IF	CITATIONS
451	A decrease in intact parathyroid hormone (iPTH) levels is associated with higher mortality in prevalent hemodialysis patients. <i>PLoS ONE</i> , 2017, 12, e0173831.	2.5	13
452	Designing a Method with Physician Participation to Assess and Improve Quality of Healthcare in Otolaryngology. <i>Journal of International Advanced Otolaryngology</i> , 2017, 13, 128-135.	1.1	0
453	Apoptosis inducing factor (AIF) mediates lethal redox stress induced by menadione. <i>Oncotarget</i> , 2016, 7, 76496-76507.	2.0	20
454	Urinary Kininogen-1 and Retinol binding protein-4 respond to Acute Kidney Injury: predictors of patient prognosis?. <i>Scientific Reports</i> , 2016, 6, 19667.	3.4	23
455	Time to treatment benefit for adult patients with Fabry disease receiving agalsidase Î²: data from the Fabry Registry. <i>Journal of Medical Genetics</i> , 2016, 53, 495-502.	3.5	111
456	Proteomic prediction and Renin angiotensin aldosterone system Inhibition prevention Of early diabetic nephropathy in Type 2 diabetic patients with normoalbuminuria (PRIORITY): essential study design and rationale of a randomised clinical multicentre trial. <i>BMJ Open</i> , 2016, 6, e010310.	2.1	106
457	Downregulation of kidney protective factors by inflammation: role of transcription factors and epigenetic mechanisms. <i>American Journal of Physiology - Renal Physiology</i> , 2016, 311, F1329-F1340.	2.8	54
458	Therapeutic variability in adult minimal change disease and focal segmental glomerulosclerosis. <i>CKJ: Clinical Kidney Journal</i> , 2016, 9, 381-386.	2.7	12
459	Chronicity following ischaemia-reperfusion injury depends on tubular-macrophage crosstalk involving two tubular cell-derived CSF-1R activators: CSF-1 and IL-34. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 1409-1416.	0.7	20
460	Clinical management of the uraemic syndrome in chronic kidney disease. <i>Lancet Diabetes and Endocrinology</i> , 2016, 4, 360-373.	11.1	79
461	Atrial fibrillation in chronic kidney disease. <i>European Journal of Internal Medicine</i> , 2016, 33, 3-13.	2.2	14
462	Hypertension in Chronic Kidney Disease Part 1. <i>Hypertension</i> , 2016, 67, 1093-1101.	4.9	64
463	Hypertension in Chronic Kidney Disease Part 2. <i>Hypertension</i> , 2016, 67, 1102-1110.	4.9	88
464	Histone lysine crotonylation during acute kidney injury in mice. <i>DMM Disease Models and Mechanisms</i> , 2016, 9, 633-645.	2.4	101
465	Creatinine Clearance Is Not Equal to Glomerular Filtration Rate and Cockcroft-Gault Equation Is Not Equal to CKD-EPI Collaboration Equation. <i>American Journal of Medicine</i> , 2016, 129, 1259-1263.	1.4	57
466	Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990â€“2015: a systematic analysis for the Global Burden of Disease Study 2015. <i>Lancet</i> , 2016, 388, 1603-1658.	11.9	1,680
467	Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980â€“2015: a systematic analysis for the Global Burden of Disease Study 2015. <i>Lancet</i> , 2016, 388, 1459-1544.	11.9	5,141
468	Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990â€“2015: a systematic analysis for the Global Burden of Disease Study 2015. <i>Lancet</i> , 2016, 388, 1545-1602.	11.9	5,538

#	ARTICLE	IF	CITATIONS
469	Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990â€“2015: a systematic analysis for the Global Burden of Disease Study 2015. <i>Lancet, The</i> , 2016, 388, 1659-1724.	11.9	4,401
470	Measuring the health-related Sustainable Development Goals in 188 countries: a baseline analysis from the Global Burden of Disease Study 2015. <i>Lancet, The</i> , 2016, 388, 1813-1850.	11.9	433
471	Risk factors for severe clinical events in male and female patients with Fabry disease treated with agalsidase beta enzyme replacement therapy: Data from the Fabry Registry. <i>Molecular Genetics and Metabolism</i> , 2016, 119, 151-159.	2.1	40
472	<sc>PCSK</sc>9 in diabetic kidney disease. <i>European Journal of Clinical Investigation</i> , 2016, 46, 779-786.	3.4	23
473	Calcineurin inhibitors cyclosporine A and tacrolimus induce vascular inflammation and endothelial activation through TLR4 signaling. <i>Scientific Reports</i> , 2016, 6, 27915.	3.4	89
474	HIV and kidney diseases: 35 years of history and consequences. <i>CKJ: Clinical Kidney Journal</i> , 2016, 9, 772-781.	2.7	47
475	Non-canonical NFÎ²B activation promotes chemokine expression in podocytes. <i>Scientific Reports</i> , 2016, 6, 28857.	3.4	28
476	Out of the TWEAKlight: Elucidating the Role of Fn14 and TWEAK in Acute Kidney Injury. <i>Seminars in Nephrology</i> , 2016, 36, 189-198.	1.5	37
477	CÃ³mo debemos analizar y describir la mortalidad de nuestros pacientes: experiencia del Grupo Centro DiÃ¡lisis Peritoneal. <i>Nefrología</i> , 2016, 36, 149-155.	0.6	4
478	Corrigendum to â€œIRS2 and PTEN are key molecules in controlling insulin sensitivity in podocytesâ€• [Biochim. Biophys. Acta 1853 (12) (2015) 3224â€“3234]. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2016, 1863, 786.	4.0	1
479	Small vessel microembolization and acute glomerulonephritis following infection of aesthetic filler implants. <i>Diagnostic Pathology</i> , 2016, 11, 2.	2.0	6
480	Targeting inflammation in diabetic kidney disease: early clinical trials. <i>Expert Opinion on Investigational Drugs</i> , 2016, 25, 1045-1058.	4.0	69
481	NFÎ²B protein downregulation in acute kidney injury: Modulation of inflammation and survival in tubular cells. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2016, 1862, 635-646.	3.7	27
482	Focus on renal congestion in heart failure. <i>CKJ: Clinical Kidney Journal</i> , 2016, 9, 39-47.	2.7	82
483	Computerized clinical decision support for the early recognition and management of acute kidney injury: a qualitative evaluation of end-user experience. <i>CKJ: Clinical Kidney Journal</i> , 2016, 9, 57-62.	2.7	21
484	Priority topics for European multidisciplinary guidelines on the management of chronic kidney disease in older adults. <i>International Urology and Nephrology</i> , 2016, 48, 859-869.	1.4	14
485	Relevance of uric acid and asymmetric dimethylarginine for modeling cardiovascular risk prediction in chronic kidney disease patients. <i>International Urology and Nephrology</i> , 2016, 48, 1129-1136.	1.4	20
486	Osteoprotegerin in Chronic Kidney Disease: Associations with Vascular Damage and Cardiovascular Events. <i>Calcified Tissue International</i> , 2016, 99, 121-130.	3.1	22

#	ARTICLE	IF	CITATIONS
487	Picophytoplankton contribution to <i>Mytilus edulis</i> growth in an intensive culture environment. <i>Marine Biology</i> , 2016, 163, 1.	1.5	39
488	Serum uric acid and AKI: is it time?. <i>CKJ: Clinical Kidney Journal</i> , 2016, 9, 48-50.	2.7	11
489	Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best Practice. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 337-348.	0.7	212
490	Atherosclerotic renal artery stenosis in the post-CORAL era part 1: the renal penumbra concept and next-generation functional diagnostic imaging. <i>Journal of the American Society of Hypertension</i> , 2016, 10, 360-367.	2.4	11
491	Anatomical structure and topographic anatomy of sciatic nerve in human fetuses. <i>Journal of the Anatomical Society of India</i> , 2016, 65, S25-S32.	0.2	3
492	The structure of a second-degree $\langle \text{mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" altimg="si1.gif" display="inline" overflow="scroll"} \rangle \langle \text{mml:mi} \rangle D \langle \text{mml:mi} \rangle \langle \text{mml:math} \rangle$ -invariant subspace and its application in ideal interpolation. <i>Journal of Approximation Theory</i> , 2016, 207, 232-240.	0.8	3
493	Atherosclerotic renal artery stenosis in the post-CORAL era part 2: new directions in Transcatheter Nephron Salvage following flawed revascularization trials. <i>Journal of the American Society of Hypertension</i> , 2016, 10, 368-377.	2.4	14
494	Adaptability of stride-to-stride control of stepping movements in human walking. <i>Journal of Biomechanics</i> , 2016, 49, 229-237.	2.0	39
495	The Choice of Hemodialysis Membrane Affects Bisphenol A Levels in Blood. <i>Journal of the American Society of Nephrology: JASN</i> , 2016, 27, 1566-1574.	0.5	64
496	The inflammatory cytokine TWEAK decreases PGC-1 $\beta$ expression and mitochondrial function in acute kidney injury. <i>Kidney International</i> , 2016, 89, 399-410.	5.3	107
497	Important abnormalities of bone mineral metabolism are present in patients with coronary artery disease with a mild decrease of the estimated glomerular filtration rate. <i>Journal of Bone and Mineral Metabolism</i> , 2016, 34, 587-598.	2.8	13
498	Regulation and production of Tcf, a cable-like fimbriae from <i>Salmonella enterica</i> serovar Typhi. <i>Microbiology (United Kingdom)</i> , 2016, 162, 777-788.	1.7	18
499	Evaluation of the efficacy and safety of three dosing regimens of agalsidase alfa enzyme replacement therapy was underpowered. <i>Drug Design, Development and Therapy</i> , 2015, 9, 5873.	4.2	1
500	Horizon 2020 in Diabetic Kidney Disease: The Clinical Trial Pipeline for Add-On Therapies on Top of Renin Angiotensin System Blockade. <i>Journal of Clinical Medicine</i> , 2015, 4, 1325-1347.	2.5	52
501	CD74 in Kidney Disease. <i>Frontiers in Immunology</i> , 2015, 6, 483.	4.8	26
502	Mathematical Modeling of Early Cellular Innate and Adaptive Immune Responses to Ischemia/Reperfusion Injury and Solid Organ Allotransplantation. <i>Frontiers in Immunology</i> , 2015, 6, 484.	4.8	16
503	Modifiable Risk Factors for Increased Arterial Stiffness in Outpatient Nephrology. <i>PLoS ONE</i> , 2015, 10, e0123903.	2.5	3
504	Paricalcitol Inhibits Aldosterone-Induced Proinflammatory Factors by Modulating Epidermal Growth Factor Receptor Pathway in Cultured Tubular Epithelial Cells. <i>BioMed Research International</i> , 2015, 1-13.	1.9	19

#	ARTICLE	IF	CITATIONS
505	TGF-Beta Blockade Increases Renal Inflammation Caused by the C-Terminal Module of the CCN2. Mediators of Inflammation, 2015, 2015, 1-10.	3.0	16
506	Pathogenesis of glomerular haematuria. World Journal of Nephrology, 2015, 4, 185.	2.0	34
507	Welcome to the new ckj: an open-access resource integrating clinical, translational and educational research into clinical practice. CKJ: Clinical Kidney Journal, 2015, 8, 1-2.	2.7	2
508	Translational nephrology: what translational research is and a bird's-eye view on translational research in nephrology. CKJ: Clinical Kidney Journal, 2015, 8, 14-22.	2.7	18
509	Chronic kidney disease and an uncertain diagnosis of Fabry disease: Approach to a correct diagnosis. Molecular Genetics and Metabolism, 2015, 114, 242-247.	2.1	52
510	Kidney tissue proteomics reveals regucalcin downregulation in response to diabetic nephropathy with reflection in urinary exosomes. Translational Research, 2015, 166, 474-484.e4.	5.1	65
511	Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990â€“2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet, The, 2015, 386, 743-800.	11.9	5,124
512	2012 ERA-EDTA Registry Annual Report: cautious optimism on outcomes, concern about persistent inequalities and data black-outs. CKJ: Clinical Kidney Journal, 2015, 8, 243-247.	2.7	14
513	Use of sevelamer in chronic kidney disease: beyond phosphorus control. Nefrologia, 2015, 35, 207-217.	0.4	10
514	Haemodialysate: long neglected, difficult to optimize, may modify hard outcomes. CKJ: Clinical Kidney Journal, 2015, 8, 576-579.	2.7	6
515	Granulomatous interstitial nephritis: a chameleon in a globalized world. CKJ: Clinical Kidney Journal, 2015, 8, 511-515.	2.7	8
516	The fate of triaged and rejected manuscripts. Nephrology Dialysis Transplantation, 2015, 30, 1947-1950.	0.7	9
517	Humble kidneys predict mighty heart troubles. Lancet Diabetes and Endocrinology, the, 2015, 3, 489-491.	11.1	16
518	Thrombotic microangiopathy: expanding genetic, clinical and therapeutic spectra and the need for worldwide implementation of recent advances. CKJ: Clinical Kidney Journal, 2015, 8, 686-689.	2.7	3
519	Association between the IL17RA rs4819554 polymorphism and reduced renal filtration rate in the Spanish RENASTUR cohort. Human Immunology, 2015, 76, 75-78.	2.5	20
520	TNF-related weak inducer of apoptosis (TWEAK) regulates junctional proteins in tubular epithelial cells via canonical NF- $\kappa$ B pathway and ERK activation. Journal of Cellular Physiology, 2015, 230, 1580-1593.	4.1	36
521	Diagnosis and Prediction of CKD Progression by Assessment of Urinary Peptides. Journal of the American Society of Nephrology: JASN, 2015, 26, 1999-2010.	0.5	208
522	Peritoneal Dialysis can be an Option for Dominant Polycystic Kidney Disease: An Observational Study. Peritoneal Dialysis International, 2015, 35, 530-536.	2.7	20

#	ARTICLE	IF	CITATIONS
523	Identification and genomic analysis of a novel member of Microviridae, IME-16, through high-throughput sequencing. <i>Virologica Sinica</i> , 2015, 30, 301-304.	3.0	1
524	Lyso-Gb3 activates Notch1 in human podocytes. <i>Human Molecular Genetics</i> , 2015, 24, 5720-5732.	3.0	113
525	Healthcare-associated infections: new challenges looking for answers. <i>CKJ: Clinical Kidney Journal</i> , 2015, 8, 100-101.	2.7	3
526	Combination use of medicines from two classes of renin-angiotensin system blocking agents: risk of hyperkalemia, hypotension, and impaired renal function. <i>Therapeutic Advances in Drug Safety</i> , 2015, 6, 166-176.	2.4	37
527	Decreasing incidence of renal replacement therapy over time at the critical 50-59-year age range suggests a role for nephroprotective therapy in ADPKD. <i>Kidney International</i> , 2015, 88, 194.	5.3	6
528	Validity of Vascular Calcification as a Screening Tool and as a Surrogate End Point in Clinical Research. <i>Hypertension</i> , 2015, 66, 3-9.	4.9	23
529	Angiotensin II, via angiotensin receptor type 1/nuclear factor- $\kappa$ B activation, causes a synergistic effect on interleukin-1 $\beta$ -induced inflammatory responses in cultured mesangial cells. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2015, 16, 23-32.	1.6	24
530	Designing drugs that combat kidney damage. <i>Expert Opinion on Drug Discovery</i> , 2015, 10, 541-556.	5.1	26
531	Translational value of animal models of kidney failure. <i>European Journal of Pharmacology</i> , 2015, 759, 205-220.	3.5	70
532	A European multicentre and open-label controlled randomized trial to evaluate the efficacy of sequential treatment with Tacrolimus-Rituximab versus steroids plus cyclophosphamide in patients with primary Membranous Nephropathy: the STARMEN study. <i>CKJ: Clinical Kidney Journal</i> , 2015, 8, 503-510.	2.7	48
533	Optimizing haemodialysate composition. <i>CKJ: Clinical Kidney Journal</i> , 2015, 8, 580-589.	2.7	49
534	Phosphodiesterase type 5 inhibitors and kidney disease. <i>International Urology and Nephrology</i> , 2015, 47, 1521-1528.	1.4	34
535	Guest Editorial: Sparse Coding. <i>International Journal of Computer Vision</i> , 2015, 114, 89-90.	15.9	1
536	Timing of eculizumab therapy for C3 glomerulonephritis. <i>CKJ: Clinical Kidney Journal</i> , 2015, 8, 449-452.	2.7	15
537	IRS2 and PTEN are key molecules in controlling insulin sensitivity in podocytes. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2015, 1853, 3224-3234.	4.0	27
538	The double challenge of resistant hypertension and chronic kidney disease. <i>Lancet, The</i> , 2015, 386, 1588-1598.	11.9	154
539	Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990-2013: quantifying the epidemiological transition. <i>Lancet, The</i> , 2015, 386, 2145-2191.	11.9	1,594
540	Uso del sevelamer en la enfermedad renal crónica. Más allá del control del fósforo. <i>Nefrología</i> , 2015, 35, 207-217.	0.6	18

#	ARTICLE	IF	CITATIONS
541	The alpha-galactosidase A p.Arg118Cys variant does not cause a Fabry disease phenotype: Data from individual patients and family studies. <i>Molecular Genetics and Metabolism</i> , 2015, 114, 248-258.	2.1	76
542	The C-Terminal Module IV of Connective Tissue Growth Factor, Through EGFR/Nox1 Signaling, Activates the NF- $\kappa$ B Pathway and Proinflammatory Factors in Vascular Smooth Muscle Cells. <i>Antioxidants and Redox Signaling</i> , 2015, 22, 29-47.	5.4	33
543	'That Obscure Object of Desire': in systemic lupus erythematosus B-cell activating factor/B-lymphocyte stimulator is targeted both by the immune system and by physicians. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, 394-400.	0.7	4
544	Tradition ... Tradition .... <i>Journal of the Pediatric Infectious Diseases Society</i> , 2015, 4, 132-133.	1.2	1
545	Klotho Prevents NF- $\kappa$ B Translocation and Protects Endothelial Cell From Senescence Induced by Uremia. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2015, 70, 1198-1209.	3.7	78
546	Impaired Vitamin D Signaling in Endothelial Cell Leads to an Enhanced Leukocyte-Endothelium Interplay: Implications for Atherosclerosis Development. <i>PLoS ONE</i> , 2015, 10, e0136863.	2.5	52
547	The broccoli-born isothiocyanate sulforaphane impairs nucleotide excision repair: XPA as one potential target. <i>Archives of Toxicology</i> , 2014, 88, 647-58.	4.2	23
548	3,4-DGE is cytotoxic and decreases HSP27/HSPB1 in podocytes. <i>Archives of Toxicology</i> , 2014, 88, 597-608.	4.2	21
549	Gremlin Activates the Smad Pathway Linked to Epithelial Mesenchymal Transdifferentiation in Cultured Tubular Epithelial Cells. <i>BioMed Research International</i> , 2014, 2014, 1-11.	1.9	45
550	TWEAK and the progression of renal disease: clinical translation. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, i54-i62.	0.7	95
551	Assessment of arterial stiffness for clinical and epidemiological studies: methodological considerations for validation and entry into the European Renal and Cardiovascular Medicine registry. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, 232-239.	0.7	82
552	Bicarbonate therapy, phosphate binders, and risk for vascular calcification. <i>Kidney International</i> , 2014, 86, 1056.	5.3	5
553	Integrin-linked kinase plays a key role in the regulation of angiotensin II-induced renal inflammation. <i>Clinical Science</i> , 2014, 127, 19-31.	4.2	40
554	p-Cresyl sulphate has pro-inflammatory and cytotoxic actions on human proximal tubular epithelial cells. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, 56-64.	0.7	78
555	Relevant role of PKG in the progression of fibrosis induced by TNF-like weak inducer of apoptosis. <i>American Journal of Physiology - Renal Physiology</i> , 2014, 307, F75-F85.	2.8	14
556	Galectin-3, a Biomarker Linking Oxidative Stress and Inflammation With the Clinical Outcomes of Patients With Atherothrombosis. <i>Journal of the American Heart Association</i> , 2014, 3, .	3.8	122
557	Tumor necrosis factor-like weak inducer of apoptosis (TWEAK) and kidney disease. <i>Current Opinion in Nephrology and Hypertension</i> , 2014, 23, 93-100.	2.0	19
558	Mitochondria-targeted therapies for acute kidney injury " ERRATUM. <i>Expert Reviews in Molecular Medicine</i> , 2014, 16, .	3.9	2



#	ARTICLE	IF	CITATIONS
559	Mitochondria-targeted therapies for acute kidney injury. <i>Expert Reviews in Molecular Medicine</i> , 2014, 16, e13.	3.9	77
560	Role of chemokines in proteinuric kidney disorders. <i>Expert Reviews in Molecular Medicine</i> , 2014, 16, e3.	3.9	21
561	CXCL16 in kidney and cardiovascular injury. <i>Cytokine and Growth Factor Reviews</i> , 2014, 25, 317-325.	7.5	59
562	Macrophages and Recently Identified Forms of Cell Death. <i>International Reviews of Immunology</i> , 2014, 33, 9-22.	3.3	15
563	Therapeutic approaches to diabetic nephropathy—beyond the RAS. <i>Nature Reviews Nephrology</i> , 2014, 10, 325-346.	9.3	155
564	Next-Generation Phosphate Binders: Focus on Iron-Based Binders. <i>Drugs</i> , 2014, 74, 863-877.	10.8	23
565	Endogenous NAMPT dampens chemokine expression and apoptotic responses in stressed tubular cells. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2014, 1842, 293-303.	3.7	16
566	Diabetic nephropathy induces changes in the proteome of human urinary exosomes as revealed by label-free comparative analysis. <i>Journal of Proteomics</i> , 2014, 96, 92-102.	2.5	133
567	Vascular calcification in chronic kidney disease: are biomarkers useful for probing the pathobiology and the health risks of this process in the clinical scenario?. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, 1275-1284.	0.7	50
568	Deferasirox nephrotoxicity—the knowns and unknowns. <i>Nature Reviews Nephrology</i> , 2014, 10, 574-586.	9.3	64
569	CKD hotspots around the world: where, why and what the lessons are. A CKJ review series. <i>CKJ: Clinical Kidney Journal</i> , 2014, 7, 519-523.	2.7	55
570	IL-17A is a novel player in dialysis-induced peritoneal damage. <i>Kidney International</i> , 2014, 86, 303-315.	5.3	76
571	Urine 2D proteome analysis in healthy condition and kidney disease. <i>Electrophoresis</i> , 2014, 35, 2634-2641.	2.8	16
572	Spanish guidelines for the management of autosomal dominant polycystic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, iv95-iv105.	0.7	57
573	Unilateral ureteral obstruction: beyond obstruction. <i>International Urology and Nephrology</i> , 2014, 46, 765-776.	1.4	165
574	Osteoprotegerin and kidney disease. <i>Journal of Nephrology</i> , 2014, 27, 607-617.	2.1	35
575	Multicentre prospective validation of a urinary peptidome-based classifier for the diagnosis of type 2 diabetic nephropathy. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, 1563-1570.	0.7	106
576	Differential effects of oral and intravenous L-carnitine on serum lipids: is the microbiota the answer?. <i>CKJ: Clinical Kidney Journal</i> , 2014, 7, 437-441.	2.7	7

#	ARTICLE	IF	CITATIONS
577	Epidemiology, contributors to, and clinical trials of mortality risk in chronic kidney failure. <i>Lancet, The</i> , 2014, 383, 1831-1843.	11.9	354
578	TWEAK Promotes Peritoneal Inflammation. <i>PLoS ONE</i> , 2014, 9, e90399.	2.5	21
579	Molecular mediators of favism-induced acute kidney injury. <i>Clinical Nephrology</i> , 2014, 81, 203-209.	0.7	12
580	Cortisol levels are associated with mortality risk in hemodialysis patients. <i>Clinical Nephrology</i> , 2014, 82 (2014), 247-256.	0.7	13
581	Correction of hypocalcemia allows optimal recruitment of FGF-23-dependent phosphaturic mechanisms in acute hyperphosphatemia post-phosphate enema. <i>Journal of Bone and Mineral Metabolism</i> , 2013, 31, 703-707.	2.8	8
582	TNF-related weak inducer of apoptosis (TWEAK) promotes kidney fibrosis and Ras-dependent proliferation of cultured renal fibroblast. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2013, 1832, 1744-1755.	3.7	91
583	Fibrosis: a key feature of Fabry disease with potential therapeutic implications. <i>Orphanet Journal of Rare Diseases</i> , 2013, 8, 116.	2.8	133
584	Fn14 in podocytes and proteinuric kidney disease. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2013, 1832, 2232-2243.	3.7	50
585	A CLCNKA polymorphism (rs10927887; p.Arg83Gly) previously linked to heart failure is associated with the estimated glomerular filtration rate in the RENASTUR cohort. <i>Gene</i> , 2013, 527, 670-672.	2.3	9
586	The demise of calcium-based phosphate binders. <i>Lancet, The</i> , 2013, 382, 1232-1234.	11.9	14
587	Calcineurin inhibitors recruit protein kinases JAK2 and JNK, TLR signaling and the UPR to activate NF- $\kappa$ B-mediated inflammatory responses in kidney tubular cells. <i>Toxicology and Applied Pharmacology</i> , 2013, 272, 825-841.	2.9	40
588	Pulmonary Hypertension in CKD. <i>American Journal of Kidney Diseases</i> , 2013, 61, 612-622.	1.9	129
589	Klotho to Treat Kidney Fibrosis. <i>Journal of the American Society of Nephrology: JASN</i> , 2013, 24, 687-689.	0.5	35
590	Progress in the development of animal models of acute kidney injury and its impact on drug discovery. <i>Expert Opinion on Drug Discovery</i> , 2013, 8, 879-895.	5.1	29
591	The use of echocardiography in observational clinical trials: the EURECA-m registry. <i>Nephrology Dialysis Transplantation</i> , 2013, 28, 19-23.	0.7	15
592	Fabry nephropathy: indications for screening and guidance for diagnosis and treatment by the European Renal Best Practice. <i>Nephrology Dialysis Transplantation</i> , 2013, 28, 505-517.	0.7	81
593	The C-terminal module IV of connective tissue growth factor is a novel immune modulator of the Th17 response. <i>Laboratory Investigation</i> , 2013, 93, 812-824.	3.9	42
594	Rituximab-associated interstitial lung disease in fibrillary glomerulonephritis. <i>CKJ: Clinical Kidney Journal</i> , 2013, 6, 510-512.	2.7	2

#	ARTICLE	IF	CITATIONS
595	Subclinical versus overt obesity in dialysis patients: more than meets the eye. <i>Nephrology Dialysis Transplantation</i> , 2013, 28, iv175-iv181.	0.7	34
596	TWEAK/Fn14 and Non-Canonical NF-kappaB Signaling in Kidney Disease. <i>Frontiers in Immunology</i> , 2013, 4, 447.	4.8	46
597	Connective tissue growth factor is a new ligand of epidermal growth factor receptor. <i>Journal of Molecular Cell Biology</i> , 2013, 5, 323-335.	3.3	55
598	DNA demethylation and histone H3K9 acetylation determine the active transcription of the NKG2D gene in human CD8 <sup>+</sup> T and NK cells. <i>Epigenetics</i> , 2013, 8, 66-78.	2.8	61
599	Parathyroid hormone-related protein protects renal tubuloepithelial cells from apoptosis by activating transcription factor Runx2. <i>Kidney International</i> , 2013, 83, 825-834.	5.3	20
600	TWEAK transactivation of the epidermal growth factor receptor mediates renal inflammation. <i>Journal of Pathology</i> , 2013, 231, 480-494.	4.4	49
601	Laser Therapy in Metabolic Syndrome-Related Kidney Injury. <i>Photochemistry and Photobiology</i> , 2013, 89, 953-960.	2.6	17
602	Two independent pathways of regulated necrosis mediate ischemia-reperfusion injury. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 12024-12029.	7.4	500
603	A combinatorial approach of Proteomics and Systems Biology in unravelling the mechanisms of acute kidney injury (AKI): involvement of NMDA receptor GRIN1 in murine AKI. <i>BMC Systems Biology</i> , 2013, 7, 110.	2.9	35
604	A Polymeric Nanomedicine Diminishes Inflammatory Events in Renal Tubular Cells. <i>PLoS ONE</i> , 2013, 8, e51992.	2.5	35
605	Identification of a Potent Endothelium-Derived Angiogenic Factor. <i>PLoS ONE</i> , 2013, 8, e68575.	2.5	3
606	Osteoprotegerin in Exosome-Like Vesicles from Human Cultured Tubular Cells and Urine. <i>PLoS ONE</i> , 2013, 8, e72387.	2.5	53
607	Hyperlipidemia-Associated Renal Damage Decreases Klotho Expression in Kidneys from ApoE Knockout Mice. <i>PLoS ONE</i> , 2013, 8, e83713.	2.5	57
608	GSK3, Snail, and Adhesion Molecule Regulation by Cyclosporine A in Renal Tubular Cells. <i>Toxicological Sciences</i> , 2012, 127, 425-437.	3.1	31
609	Undetectable serum calcidiol: not everything that glitters is gold. <i>CKJ: Clinical Kidney Journal</i> , 2012, 5, 37-40.	2.7	7
610	Fabry disease: the many faces of a single disorder. <i>CKJ: Clinical Kidney Journal</i> , 2012, 5, 379-382.	2.7	5
611	AKI Associated with Macroscopic Glomerular Hematuria. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2012, 7, 175-184.	4.3	117
612	Activation of Liver X Receptor Inhibits Osteopontin and Ameliorates Diabetic Nephropathy. <i>Journal of the American Society of Nephrology: JASN</i> , 2012, 23, 1835-1846.	0.5	49

#	ARTICLE	IF	CITATIONS
613	HSP27/HSPB1 as an adaptive podocyte antiapoptotic protein activated by high glucose and angiotensin II. <i>Laboratory Investigation</i> , 2012, 92, 32-45.	3.9	56
614	The Human Plasma Lipidome. <i>New England Journal of Medicine</i> , 2012, 366, 668-669.	29.6	7
615	Recommendations on Reintroduction of Agalsidase Beta for Patients with Fabry Disease in Europe, Following a Period of Shortage. <i>JIMD Reports</i> , 2012, 8, 51-56.	1.2	9
616	Pharmacological modulation of peritoneal injury induced by dialysis fluids: is it an option?. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 478-481.	0.7	18
617	Dual-Specificity Phosphatases Are Implicated in Severe Hyperplasia and Lack of Response to FGF23 of Uremic Parathyroid Glands from Rats. <i>Endocrinology</i> , 2012, 153, 1627-1637.	2.8	15
618	Vitamin D receptor activation and cardiovascular disease. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, iv17-iv21.	0.7	55
619	Antioxidants in Kidney Diseases: The Impact of Bardoxolone Methyl. <i>International Journal of Nephrology</i> , 2012, 2012, 1-11.	1.4	48
620	Phosphorus and Nutrition in Chronic Kidney Disease. <i>International Journal of Nephrology</i> , 2012, 2012, 1-5.	1.4	54
621	Renal outcomes of agalsidase beta treatment for Fabry disease: role of proteinuria and timing of treatment initiation. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 1042-1049.	0.7	134
622	Klotho, phosphate and inflammation/ageing in chronic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, iv6-iv10.	0.7	91
623	Combination therapy with an angiotensin II receptor blocker and an HMG-CoA reductase inhibitor in experimental subtotal nephrectomy. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 2720-2733.	0.7	9
624	Haematuria: the forgotten CKD factor?. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 28-34.	0.7	77
625	Notch3 and kidney injury: never two without three. <i>Journal of Pathology</i> , 2012, 228, 266-273.	4.4	22
626	High prevalence of winter 25-hydroxyvitamin D deficiency despite supplementation according to guidelines for hemodialysis patients. <i>Clinical and Experimental Nephrology</i> , 2012, 16, 945-951.	1.6	18
627	Cardiovascular risk biomarkers in CKD: the inflammation link and the road less traveled. <i>International Urology and Nephrology</i> , 2012, 44, 1731-1744.	1.4	36
628	A role for the membrane proteome in human chronic kidney disease erythrocytes. <i>Translational Research</i> , 2012, 160, 374-383.	5.1	18
629	Association between a common KCNJ11 polymorphism (rs5219) and new-onset posttransplant diabetes in patients treated with Tacrolimus. <i>Molecular Genetics and Metabolism</i> , 2012, 105, 525-527.	2.1	29
630	Juxtaglomerular apparatus hyperplasia under dual angiotensin blockade. A footprint of adequate RAS inhibition or a concern for renal fibrosis?. <i>BMC Nephrology</i> , 2012, 13, 21.	1.8	7

#	ARTICLE	IF	CITATIONS
631	Uromodulin, Inflammasomes, and Pyroptosis. <i>Journal of the American Society of Nephrology: JASN</i> , 2012, 23, 1761-1763.	0.5	8
632	TWEAK (tumor necrosis factor-like weak inducer of apoptosis) activates CXCL16 expression during renal tubulointerstitial inflammation. <i>Kidney International</i> , 2012, 81, 1098-1107.	5.3	62
633	Phosphate: a stealthier killer than previously thought?. <i>Cardiovascular Pathology</i> , 2012, 21, 372-381.	1.9	61
634	Klotho modulates the stress response in human senescent endothelial cells. <i>Mechanisms of Ageing and Development</i> , 2012, 133, 647-654.	4.6	56
635	Cilastatin protects against cisplatin-induced nephrotoxicity without compromising its anticancer efficiency in rats. <i>Kidney International</i> , 2012, 82, 652-663.	5.3	85
636	Clinical usefulness of novel prognostic biomarkers in patients on hemodialysis. <i>Nature Reviews Nephrology</i> , 2012, 8, 141-150.	9.3	44
637	Inflammatory Cytokines and Survival Factors from Serum Modulate Tweak-Induced Apoptosis in PC-3 Prostate Cancer Cells. <i>PLoS ONE</i> , 2012, 7, e47440.	2.5	19
638	Beyond proteinuria: VDR activation reduces renal inflammation in experimental diabetic nephropathy. <i>American Journal of Physiology - Renal Physiology</i> , 2012, 302, F647-F657.	2.8	152
639	Monocyte subpopulations and cardiovascular risk in chronic kidney disease. <i>Nature Reviews Nephrology</i> , 2012, 8, 362-369.	9.3	149
640	Implementation of proteomic biomarkers: making it work. <i>European Journal of Clinical Investigation</i> , 2012, 42, 1027-1036.	3.4	154
641	Angiotensin II Contributes to Renal Fibrosis Independently of Notch Pathway Activation. <i>PLoS ONE</i> , 2012, 7, e40490.	2.5	37
642	Is it or is it not a pathogenic mutation? Is it or is it not the podocyte?. <i>Journal of Nephropathology</i> , 2012, 1, 152-154.	0.2	13
643	Acute renal failure associated to paroxysmal nocturnal haemoglobinuria leads to intratubular haemosiderin accumulation and CD163 expression. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 3408-3411.	0.7	57
644	Paricalcitol for reduction of albuminuria in diabetes. <i>Lancet, The</i> , 2011, 377, 635-636.	11.9	15
645	Tenofovir Nephrotoxicity: 2011 Update. <i>AIDS Research and Treatment</i> , 2011, 2011, 1-11.	0.7	213
646	High-Performance Capillary Electrophoresis for Determining HIV-1 Tat Protein in Neurons. <i>PLoS ONE</i> , 2011, 6, e16148.	2.5	19
647	Immunisation with Recombinant PfEMP1 Domains Elicits Functional Rosette-Inhibiting and Phagocytosis-Inducing Antibodies to <i>Plasmodium falciparum</i> . <i>PLoS ONE</i> , 2011, 6, e16414.	2.5	44
648	Restoring Coastal Plants to Improve Global Carbon Storage: Reaping What We Sow. <i>PLoS ONE</i> , 2011, 6, e18311.	2.5	72

#	ARTICLE	IF	CITATIONS
649	Etiopathology of chronic tubular, glomerular and renovascular nephropathies: Clinical implications. <i>Journal of Translational Medicine</i> , 2011, 9, 13.	4.4	129
650	Vascular proteomics and the discovery process of clinical biomarkers: The case of TWEAK. <i>Proteomics - Clinical Applications</i> , 2011, 5, 281-288.	1.9	17
651	Proteomics in chronic kidney disease: The issues clinical nephrologists need an answer for. <i>Proteomics - Clinical Applications</i> , 2011, 5, 233-240.	1.9	20
652	Lanthanum carbonate reduces FGF23 in chronic kidney disease Stage 3 patients. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 2567-2571.	0.7	147
653	Globotriaosylsphingosine actions on human glomerular podocytes: implications for Fabry nephropathy. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 1797-1802.	0.7	178
654	The dysfunctional endothelium in CKD and in cardiovascular disease: mapping the origin(s) of cardiovascular problems in CKD and of kidney disease in cardiovascular conditions for a research agenda. <i>Kidney International Supplements</i> , 2011, 1, 6-9.	12.5	59
655	The lingering dilemma of arterial pressure in CKD: what do we know, where do we go?. <i>Kidney International Supplements</i> , 2011, 1, 17-20.	12.5	9
656	TWEAK, a multifunctional cytokine in kidney injury. <i>Kidney International</i> , 2011, 80, 708-718.	5.3	108
657	The Inflammatory Cytokines TWEAK and TNF $\alpha$ Reduce Renal Klotho Expression through NF $\kappa$ B. <i>Journal of the American Society of Nephrology: JASN</i> , 2011, 22, 1315-1325.	0.5	351
658	Soluble TWEAK and PTX3 in Nondialysis CKD Patients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2011, 6, 785-792.	4.3	92
659	The meaning of urinary creatinine concentration. <i>Kidney International</i> , 2011, 79, 791.	5.3	9
660	Animal Models of Cardiovascular Diseases. <i>BioMed Research International</i> , 2011, 2011, 497841.	1.9	294
661	Major pathways of the reno-cardiovascular link: the sympathetic and renin-angiotensin systems. <i>Kidney International Supplements</i> , 2011, 1, 13-16.	12.5	12
662	The complexity of the cardio-renal link: taxonomy, syndromes, and diseases. <i>Kidney International Supplements</i> , 2011, 1, 2-5.	12.5	28
663	Arterial aging and arterial disease: interplay between central hemodynamics, cardiac work, and organ flow-implications for CKD and cardiovascular disease. <i>Kidney International Supplements</i> , 2011, 1, 10-12.	12.5	45
664	Cardiovascular and non-cardiovascular mortality in dialysis patients: where is the link?. <i>Kidney International Supplements</i> , 2011, 1, 21-23.	12.5	39
665	PPAR- $\gamma$ agonist rosiglitazone protects peritoneal membrane from dialysis fluid-induced damage. <i>Laboratory Investigation</i> , 2010, 90, 1517-1532.	3.9	64
666	Obstructive renal injury: from fluid mechanics to molecular cell biology. <i>Research and Reports in Urology</i> , 2010, Volume 2, 41-55.	0.9	24

#	ARTICLE	IF	CITATIONS
667	Statins Inhibit Angiotensin II/Smad Pathway and Related Vascular Fibrosis, by a TGF- $\beta$ 2-Independent Process. PLoS ONE, 2010, 5, e14145.	2.5	58
668	NF- $\kappa$ B in Renal Inflammation. Journal of the American Society of Nephrology: JASN, 2010, 21, 1254-1262.	0.5	493
669	'Reality and desire' in the care of advanced chronic kidney disease. NDT Plus, 2010, 3, 431-435.	0.2	8
670	Suppressors of Cytokine Signaling Abrogate Diabetic Nephropathy. Journal of the American Society of Nephrology: JASN, 2010, 21, 763-772.	0.5	167
671	End-stage renal disease in patients with Fabry disease: natural history data from the Fabry Registry. Nephrology Dialysis Transplantation, 2010, 25, 769-775.	0.7	102
672	Caspase-12 and Diabetic Nephropathy. Journal of the American Society of Nephrology: JASN, 2010, 21, 886-888.	0.5	5
673	Local Non-Esterified Fatty Acids Correlate With Inflammation in Atheroma Plaques of Patients With Type 2 Diabetes. Diabetes, 2010, 59, 1292-1301.	0.9	50
674	The expanding spectrum of biological actions of vitamin D. Nephrology Dialysis Transplantation, 2010, 25, 2850-2865.	0.7	95
675	BASP1 Promotes Apoptosis in Diabetic Nephropathy. Journal of the American Society of Nephrology: JASN, 2010, 21, 610-621.	0.5	82
676	TNF Superfamily: A Growing Saga of Kidney Injury Modulators. Mediators of Inflammation, 2010, 2010, 1-11.	3.0	75
677	UGA hopping: a sport for nephrologists too?. Nephrology Dialysis Transplantation, 2010, 25, 2391-2395.	0.7	3
678	Prognostic Indicators of Renal Disease Progression in Adults with Fabry Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 2220-2228.	4.3	125
679	Glomerular haematuria, renal interstitial haemorrhage and acute kidney injury. Nephrology Dialysis Transplantation, 2010, 25, 4103-4106.	0.7	41
680	Unravelling fibrosis: two newcomers and an old foe. Nephrology Dialysis Transplantation, 2010, 25, 3492-3495.	0.7	15
681	BMP-7 blocks mesenchymal conversion of mesothelial cells and prevents peritoneal damage induced by dialysis fluid exposure. Nephrology Dialysis Transplantation, 2010, 25, 1098-1108.	0.7	91
682	Regulation of Vascular and Renal Cells by Common Mediators in Health and Disease: Role of the Renin-Angiotensin System in the Pathophysiology of Hypertension and Cardiovascular Disease. , 2010, , 49-63.		0
683	Functional polymorphisms in the CYP3A4, CYP3A5, and CYP21A2 genes in the risk for hypertension in pregnancy. Biochemical and Biophysical Research Communications, 2010, 397, 576-579.	2.2	14
684	Serum levels of matrix metalloproteinase-10 are associated with the severity of atherosclerosis in patients with chronic kidney disease. Kidney International, 2010, 78, 1275-1280.	5.3	37

#	ARTICLE	IF	CITATIONS
685	New paradigms in cell death in human diabetic nephropathy. <i>Kidney International</i> , 2010, 78, 737-744.	5.3	54
686	TWEAK Activates the Non-Canonical NF $\kappa$ B Pathway in Murine Renal Tubular Cells: Modulation of CCL21. <i>PLoS ONE</i> , 2010, 5, e8955.	2.5	88
687	Taming Apoptosis in Peritoneal Dialysis. <i>Peritoneal Dialysis International</i> , 2009, 29, 45-48.	2.7	4
688	Trail and kidney disease. <i>Frontiers in Bioscience</i> , 2009, Volume, 3740.	2.1	15
689	A Nanoconjugate Apaf-1 Inhibitor Protects Mesothelial Cells from Cytokine-Induced Injury. <i>PLoS ONE</i> , 2009, 4, e6634.	2.5	34
690	Nephrin mutations cause childhood- and adult-onset focal segmental glomerulosclerosis. <i>Kidney International</i> , 2009, 76, 1268-1276.	5.3	114
691	Additive Effects of Soluble TWEAK and Inflammation on Mortality in Hemodialysis Patients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2009, 4, 110-118.	4.3	106
692	Increased CD74 expression in human atherosclerotic plaques: contribution to inflammatory responses in vascular cells. <i>Cardiovascular Research</i> , 2009, 83, 586-594.	3.6	58
693	Inhibition of JAK2 protects renal endothelial and epithelial cells from oxidative stress and cyclosporin A toxicity. <i>Kidney International</i> , 2009, 75, 227-234.	5.3	49
694	Nephropathy in Fabry disease: the importance of early diagnosis and testing in high-risk populations. <i>Nephrology Dialysis Transplantation</i> , 2009, 24, 1736-1743.	0.7	33
695	TRPC6 mutational analysis in a large cohort of patients with focal segmental glomerulosclerosis. <i>Nephrology Dialysis Transplantation</i> , 2009, 24, 3089-3096.	0.7	103
696	Soluble TWEAK Plasma Levels as a Novel Biomarker of Endothelial Function in Patients with Chronic Kidney Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2009, 4, 1716-1723.	4.3	79
697	Inhibition of p38-MAPK Potentiates Cisplatin-Induced Apoptosis via GSH Depletion and Increases Intracellular Drug Accumulation in Growth-Arrested Kidney Tubular Epithelial Cells. <i>Toxicological Sciences</i> , 2009, 111, 413-423.	3.1	24
698	Tumor Necrosis Factor $\alpha$ -Like Weak Inducer of Apoptosis (TWEAK) Enhances Vascular and Renal Damage Induced by Hyperlipidemic Diet in ApoE-Knockout Mice. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2009, 29, 2061-2068.	3.9	102
699	Tweak induces proliferation in renal tubular epithelium: a role in uninephrectomy induced renal hyperplasia. <i>Journal of Cellular and Molecular Medicine</i> , 2009, 13, 3329-3342.	3.5	91
700	Considering TWEAK as a target for therapy in renal and vascular injury. <i>Cytokine and Growth Factor Reviews</i> , 2009, 20, 251-258.	7.5	57
701	PatogĂ©nesis de la malnutriciĂ³n en pacientes en diĂ¡lisis con Ă©nfasis en los aspectos mĂ¡s especĂ©ficos de la diĂ¡lisis peritoneal. <i>Dialisis Y Trasplante</i> , 2009, 30, 57-62.	0.1	0
702	Estrategias en la profilaxis y el tratamiento de la malnutriciĂ³n en diĂ¡lisis peritoneal: un problema infradiagnosticado. <i>Dialisis Y Trasplante</i> , 2009, 30, 93-99.	0.1	0



#	ARTICLE	IF	CITATIONS
703	Pharmacological Modulation of Epithelial Mesenchymal Transition Caused by Angiotensin II. Role of ROCK and MAPK Pathways. <i>Pharmaceutical Research</i> , 2008, 25, 2447-2461.	3.5	64
704	A search for cyclophilin A gene variants in cyclosporine A-treated renal transplanted patients. <i>Clinical Transplantation</i> , 2008, 22, 722-729.	1.6	17
705	Females with Fabry disease frequently have major organ involvement: Lessons from the Fabry Registry. <i>Molecular Genetics and Metabolism</i> , 2008, 93, 112-128.	2.1	453
706	Nephropathy in males and females with Fabry disease: cross-sectional description of patients before treatment with enzyme replacement therapy. <i>Nephrology Dialysis Transplantation</i> , 2008, 23, 1600-1607.	0.7	190
707	Hyperphosphatemia and hyperparathyroidism in incident chronic kidney disease patients. <i>Kidney International</i> , 2008, 74, S88-S93.	5.3	21
708	Angiotensin II activates the Smad pathway during epithelial mesenchymal transdifferentiation. <i>Kidney International</i> , 2008, 74, 585-595.	5.3	110
709	Recommendations and guidelines for the diagnosis and treatment of Fabry nephropathy in adults. <i>Nature Clinical Practice Nephrology</i> , 2008, 4, 327-336.	0.9	71
710	Efficacy and safety of sevelamer hydrochloride and calcium acetate in patients on peritoneal dialysis. <i>Nephrology Dialysis Transplantation</i> , 2008, 24, 278-285.	0.7	70
711	3,4-Dideoxyglucosone-3-ene as a mediator of peritoneal mesothelialization. <i>Nephrology Dialysis Transplantation</i> , 2008, 23, 3307-3315.	0.7	20
712	Severe everolimus-associated pneumonitis in a renal transplant recipient. <i>Nephrology Dialysis Transplantation</i> , 2008, 23, 3353-3355.	0.7	48
713	Nephrotoxicity. , 2008, , 291-310.		1
714	ACE gene polymorphism and the prognosis and treatment of overt diabetic nephropathy. <i>Nature Clinical Practice Nephrology</i> , 2008, 4, 472-473.	0.9	2
715	A Slit in Podocyte Death. <i>Current Medicinal Chemistry</i> , 2008, 15, 1645-1654.	2.4	21
716	Bcl-xL Prevents Peritoneal Dialysis Solution-Induced Leukocyte Apoptosis. <i>Peritoneal Dialysis International</i> , 2008, 28, 48-52.	2.7	8
717	Essential Role of TGF- $\beta$ 2/Smad Pathway on Statin Dependent Vascular Smooth Muscle Cell Regulation. <i>PLoS ONE</i> , 2008, 3, e3959.	2.5	49
718	TWEAKing renal injury. <i>Frontiers in Bioscience - Landmark</i> , 2008, 13, 580.	3.1	11
719	Endovascular repair of mycotic aneurysms of the aorta: An alternative to conventional bypass surgery in patients with acute sepsis. <i>Scandinavian Journal of Infectious Diseases</i> , 2007, 39, 268-271.	1.4	7
720	Emphysematous Pyelonephritis in Dialysis Patient After Embolization of Failed Allograft. <i>Urology</i> , 2007, 70, 372.e17-372.e19.	1.4	14

#	ARTICLE	IF	CITATIONS
721	Identification of Soluble Tumor Necrosis Factor-Like Weak Inducer of Apoptosis (sTWEAK) as a Possible Biomarker of Subclinical Atherosclerosis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2007, 27, 916-922.	3.9	127
722	TWEAK and Fn14. New players in the pathogenesis of atherosclerosis. <i>Frontiers in Bioscience - Landmark</i> , 2007, 12, 3648.	3.1	48
723	Peritoneal defence lessons learned which apply to diabetes complications. <i>Nephrology Dialysis Transplantation</i> , 2006, 21, ii12-ii15.	0.7	8
724	Fn14 Is Upregulated in Cytokine-Stimulated Vascular Smooth Muscle Cells and Is Expressed in Human Carotid Atherosclerotic Plaques. <i>Stroke</i> , 2006, 37, 2044-2053.	5.0	96
725	Impact of end-stage renal disease care in planned dialysis start and type of renal replacement therapy a Spanish multicentre experience. <i>Nephrology Dialysis Transplantation</i> , 2006, 21, ii51-ii55.	0.7	82
726	3,4-DGE is Important for Side Effects in Peritoneal Dialysis What About its Role in Diabetes. <i>Current Medicinal Chemistry</i> , 2006, 13, 2695-2702.	2.4	20
727	3,4-di-deoxyglucosone-3-ene promotes leukocyte apoptosis. <i>Kidney International</i> , 2005, 68, 1303-1311.	5.3	57
728	Role of Bcl-xL in paracetamol-induced tubular epithelial cell death. <i>Kidney International</i> , 2005, 67, 592-601.	5.3	39
729	Long-Term Blood Pressure Control Prevents Oxidative Renal Injury. <i>Antioxidants and Redox Signaling</i> , 2005, 7, 1285-1293.	5.4	29
730	Angiotensin II and Reactive Oxygen Species. <i>Antioxidants and Redox Signaling</i> , 2005, 7, 1258-1260.	5.4	13
731	Tubular Cell Apoptosis and Cidofovir-Induced Acute Renal Failure. <i>Antiviral Therapy</i> , 2005, 10, 185-190.	0.9	96
732	Will Modulation of Cell Death Increase PD Technique Survival?. <i>Peritoneal Dialysis International</i> , 2004, 24, 105-114.	2.7	13
733	Tight blood pressure control decreases apoptosis during renal damage. <i>Kidney International</i> , 2004, 65, 811-822.	5.3	13
734	Persistent Proteinuria Up-Regulates Angiotensin II Type 2 Receptor and Induces Apoptosis in Proximal Tubular Cells. <i>American Journal of Pathology</i> , 2004, 164, 1817-1826.	4.0	53
735	Targeting apoptosis in acute tubular injury. <i>Biochemical Pharmacology</i> , 2003, 66, 1589-1594.	4.5	66
736	Regulation of apoptosis by lethal cytokines in human mesothelial cells. <i>Kidney International</i> , 2003, 64, 321-330.	5.3	28
737	Bcl-xL overexpression protects from apoptosis induced by HMG-CoA reductase inhibitors in murine tubular cells. <i>Kidney International</i> , 2003, 64, 181-191.	5.3	28
738	Expression of Smac/Diablo in tubular epithelial cells and during acute renal failure. <i>Kidney International</i> , 2003, 64, S52-S56.	5.3	28

#	ARTICLE	IF	CITATIONS
739	Renal expression of angiotensin type 2 (AT2) receptors during kidney damage. <i>Kidney International</i> , 2003, 64, S21-S26.	5.3	72
740	Staining for cell death. <i>Lancet, The</i> , 2003, 361, 1748.	11.9	2
741	Inhibition of Caspases Improves Bacterial Clearance in Experimental Peritonitis. <i>Peritoneal Dialysis International</i> , 2003, 23, 123-126.	2.7	24
742	Role of Endogenous Vascular Endothelial Growth Factor in Tubular Cell Protection Against Acute Cyclosporine Toxicity <sup>1</sup> . <i>Transplantation</i> , 2002, 74, 1618-1624.	1.0	39
743	Peritoneal Dialysis Retardation of Progression of Advanced Renal Failure. <i>Peritoneal Dialysis International</i> , 2002, 22, 239-242.	2.7	37
744	Role of type of vascular access in erythropoietin and intravenous iron requirements in haemodialysis. <i>Nephrology Dialysis Transplantation</i> , 2001, 16, 2188-2193.	0.7	25
745	Contribution of apoptotic cell death to renal injury. <i>Journal of Cellular and Molecular Medicine</i> , 2001, 5, 18-32.	3.5	62
746	Acceleration of Neutrophil Apoptosis by Glucose-Containing Peritoneal Dialysis Solutions: Role of Caspases. <i>Journal of the American Society of Nephrology: JASN</i> , 2001, 12, 2442-2449.	0.5	48
747	Apoptotic regulatory proteins in renal injury. <i>Kidney International</i> , 2000, 58, 467-485.	5.3	75
748	Expression of apoptosis regulatory proteins in tubular epithelium stressed in culture or following acute renal failure. <i>Kidney International</i> , 2000, 57, 969-981.	5.3	123
749	Renal cell loss through cell suicide. <i>Kidney International</i> , 2000, 58, 2235-2236.	5.3	11
750	Antiplatelet therapy alters iron requirements in hemodialysis patients. <i>American Journal of Kidney Diseases</i> , 2000, 36, 80-87.	1.9	12
751	Role and regulation of apoptotic cell death in the kidney. Y2K update. <i>Frontiers in Bioscience - Landmark</i> , 2000, 5, d735.	3.1	16
752	The Fas ligand/Fas system in renal injury. <i>Nephrology Dialysis Transplantation</i> , 1999, 14, 1831-1834.	0.7	65
753	Role of cytokines in the response to erythropoietin in hemodialysis patients. <i>Kidney International</i> , 1998, 54, 1337-1343.	5.3	131
754	Cyclosporine A induces apoptosis in murine tubular epithelial cells: Role of caspases. <i>Kidney International</i> , 1998, 54, S25-S29.	5.3	62
755	3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase and Isoprenylation Inhibitors Induce Apoptosis of Vascular Smooth Muscle Cells in Culture. <i>Circulation Research</i> , 1998, 83, 490-500.	6.5	382
756	Concentrated ascitic fluid reinfusion in cirrhotic patients: A simplified method. <i>American Journal of Kidney Diseases</i> , 1997, 29, 392-398.	1.9	5

#	ARTICLE	IF	CITATIONS
757	Anti-Fas antibodies induce cytolysis and apoptosis in cultured human mesangial cells. <i>Kidney International</i> , 1996, 49, 1064-1070.	5.3	55
758	Glomerular up-regulation of E11A and V120 fibronectin isoforms in proliferative immune complex nephritis. <i>Kidney International</i> , 1996, 50, 908-919.	5.3	13
759	Undiagnosed hepatitis C virus infection in hemodialysis patients: Value of HCV RNA and liver enzyme levels. <i>Kidney International</i> , 1996, 50, 2027-2031.	5.3	39
760	ACE inhibition reduces proteinuria, glomerular lesions and extracellular matrix production in a normotensive rat model of immune complex nephritis. <i>Kidney International</i> , 1995, 48, 1778-1791.	5.3	113
761	Role of platelet-activating factor in adriamycin-induced nephropathy in rats. <i>European Journal of Pharmacology</i> , 1987, 138, 119-123.	3.5	25
762	Apoptosis in the Kidney. , 0, , 240-249.		1
763	Differential Effects of the Second SARS-CoV-2 mRNA Vaccine Dose on T Cell Immunity in Na <sup>+</sup> ve and COVID-19 Recovered Individuals. <i>SSRN Electronic Journal</i> , 0, , .	0.3	1
764	The mysterious death of the beer drinking champ: potential role for hyperacute water loading and acute hyponatremia (HAWLAH). <i>CKJ: Clinical Kidney Journal</i> , 0, , .	2.7	2
765	Hyponatremia and subclinical chronic kidney disease. <i>European Heart Journal</i> , 0, , .	2.2	2
766	The New Guidelines of the European Association of Urology on Urolithiasis: The Urology-Nephrology Intersection. <i>Nephrology Dialysis Transplantation</i> , 0, , .	0.7	0
767	Time-averaged concentration estimation of uremic toxins with different removal kinetics: a novel approach based on intradialytic spent dialysate measurements. <i>CKJ: Clinical Kidney Journal</i> , 0, , .	2.7	0
768	The association of urinary epidermal growth factors with ADPKD disease severity and progression. <i>Nephrology Dialysis Transplantation</i> , 0, , .	0.7	0
769	NephroCheck at 10: addressing unmet needs in AKI diagnosis and risk stratification. <i>CKJ: Clinical Kidney Journal</i> , 0, , .	2.7	0
770	CKD as a risk factor for severe COVID-19: a critical look back and lessons for the future. <i>Nephrology Dialysis Transplantation</i> , 0, , .	0.7	0
771	Gender specific risk factors and outcomes of hyperkalemia in CKD patients: smoking as a driver of hyperkalemia in men. <i>CKJ: Clinical Kidney Journal</i> , 0, , .	2.7	0
772	Glomerular hyperfiltration as a therapeutic target for CKD. <i>Nephrology Dialysis Transplantation</i> , 0, , .	0.7	0
773	Incidence and outcomes of kidney replacement therapy for end-stage kidney disease due to primary glomerular disease in Europe: findings from the ERA Registry. <i>Nephrology Dialysis Transplantation</i> , 0, , .	0.7	2
774	A comparison of the epidemiology of kidney replacement therapy between Europe and the United States: 2021 data of the ERA Registry and the USRDS. <i>Nephrology Dialysis Transplantation</i> , 0, , .	0.7	6

#	ARTICLE	IF	CITATIONS
775	Hypoxia-inducible factor prolyl hydroxylase inhibitors for anaemia in chronic kidney disease: a document by the European Renal Best Practice board of the European Renal Association. Nephrology Dialysis Transplantation, 0, , .	0.7	2
776	Time trends in preemptive kidney transplantation in Europe: an ERA Registry study. Nephrology Dialysis Transplantation, 0, , .	0.7	1
777	Changes in the epidemiology of kidney replacement therapy across Europe in 2020 – the first year of the COVID-19 pandemic: an ERA Registry study. Nephrology Dialysis Transplantation, 0, , .	0.7	0
778	The impact of population ageing on the burden of chronic kidney disease. Nature Reviews Nephrology, 0, , .	9.3	0